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ABSTRACT 
JOHN THOMAS SHERIDAN: Characterizing Calcium-Activated Chloride Secretion: 
Implications for Sex-Linked Variations in Cystic Fibrosis 
(Under the direction of Dr. Robert Tarran) 
 
Cystic Fibrosis (CF) is a genetic disease that is caused by mutations in the gene 
encoding the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), the main 
Cl- channel in human airways, and is characterized by an inability to regulate salt 
transport in epithelial tissues.  In CF lungs, the airway surface liquid (ASL) dehydrates 
and mucus accumulates, resulting in mucus plugging.  This obstructs respiration and 
leaves CF patients prone to infection.  However, the Ca2+-activated Cl- channel (CaCC) 
is still present and represents an alternative channel to regulate the ASL.  Anocatmin 1 
(Ano1) was only recently identified as an essential subunit of CaCC and very little is 
known about Ano1 structure and regulation.  In our first study, we utilized several 
microscopy and biochemistry based techniques to determine the quaternary structure of 
Ano1 at the plasma membrane.  Ano1 was tagged with either mCherry or GFP to 
conduct Förster resonance energy transfer (FRET) experiments, which revealed that 
Ano1 oligomerizes prior to reaching the plasma membrane.  Additionally, altering the 
cytoplasmic concentration of Ca2+ did not affect FRET, suggesting a static interaction.  
Several biochemical assays revealed that Ano1 exists as a dimer.   
While the incidence of CF is not different between males and females, multiple 
studies have shown that CF females suffer more severely than their male counterparts.  
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This is most likely due to differences in sex hormones, such as 17β-estradiol (E2).  We 
have previously shown that acute exposure to E2 signals through estrogen receptor 
alpha (ESR1) to decrease CaCC activity by inhibiting store-operated Ca2+ entry (SOCE).  
This impinges upon airway secretion and leads to airway dehydration, which may leave 
female CF patients prone to infection.  Therefore, in our second study, we sought to 
identify the molecular mechanism that is utilized by E2/ESR1 to inhibit SOCE.  A key 
component of SOCE is stromal interaction molecule 1 (STIM1), which oligomerizes and 
translocates to the endoplasmic reticulum (ER)-plasma membrane junction following ER 
Ca2+ depletion.  Our findings reveal that E2/ESR1 inhibited STIM1 translocation, which 
correlated with a decrease in STIM1-STIM1 FRET and STIM1 mobility.  Additionally, 
exposure to E2 significantly reduced basal phosphorylation of STIM1, which has been 
shown to affect function and SOCE. Furthermore, mutating serine 575 to an alanine 
mimicked the effects of E2.  Our data indicate that E2 can signal non-genomically by 
inhibiting STIM1 phosphorylation, leading to a reduction in SOCE.  These findings 
provide insight into how E2/ESR1 may affect CF and other chronic airway diseases.
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Chapter I 
 
Background and Introduction 
 
 
1.1 Anatomy and Physiology of the Airways 
The physiological role of the lung is to oxygenate the blood through gas exchange.  
The lung is subdivided into two zones: the conducting zone and the respiration zone.  As 
air enters the respiratory system it passes through the branching network of the 
conducting zone, which is comprised of the trachea, bronchi, and bronchioles.  Here, the 
air is warmed and sterilized to prevent infection.  The air then enters the respiratory zone 
where gas exchange occurs across alveoli.   
All sections of the airways are lined with epithelia that protect the body from the 
outside world.  The conducting airways are lined with a pseudostratified epithelium that 
contains several cell types, including ciliated epithelial cells, goblet cells, and basal cells 
that work in coordination to establish and maintain a protective layer that traps inhaled 
pathogens and particles [1, 2].  The trapped pathogens are then removed from the 
airways by mucociliary clearance (MCC) or cough clearance.  MCC is a mechanical 
process where cilia beat in coordination to propel mucus up the airway tract to be 
expelled.  This ultimately prevents infection and keeps the airways clear for respiration.   
The alveoli contain several different cell types, but the alveolar surface is comprised 
of two main cell types: alveolar type I (AT1) and alveolar type II (AT2) cells [3].  AT1 cells 
are large flat cells that facilitate gas exchange.  Oxygen diffuses through AT1 cells and 
enters the blood where it binds to hemoglobin in red blood cells.  At the same time, 
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carbon dioxide is released from hemoglobin and diffuses into the alveoli, where it can be 
exhaled [4].  AT2 cells are cuboidal and secrete surfactant.  Surfactant is a substance 
rich in proteins and lipids that reduces alveolar surface tension to facilitate inflation [5].   
 
1.2 Airway Surface Liquid 
The layer of fluid that lines the airway epithelium is known as the airway surface 
liquid (ASL).  The ASL contains two distinct layers: (i) the mucus layer and (ii) the 
“watery” periciliary layer (PCL).  The latter is an ideal environment for ciliary beating [6].  
However, recent studies have shown that the PCL also contains mucins that are 
tethered to the cilia [7].  The mucus layer sits atop the cilia and forms a gel that is 
comprised of several mucins, with MUC5AC and MUC5B predominating [8].  ASL 
hydration must be properly maintained to function correctly.  This achieved by regulating 
secretion and absorption of salts via several ion channels.   
In human airways, the Cystic Fibrosis Transmembrane Conductance Regulator 
(CFTR) is the main chloride (Cl-) channel that regulates ASL hydration (Fig. 1.1).  When 
CFTR is activated by an elevation in cAMP, Cl- and bicarbonate are secreted into the 
ASL [9, 10].  Activation of CFTR also inhibits sodium (Na+) absorption through the 
epithelial Na+ channel (ENaC) [9].  This creates osmotic pressure, which promotes 
movement of water into the ASL, thus providing hydration.  ENaC is a heterotrimer and 
is comprised of three separate subunits termed: α, β, and γ [11].  To activate ENaC and 
initiate Na+ absorption, proteases residing in the ASL cleave ENaC, inducing a 
conformational change that opens the channel [11].  ENaC can also be regulated by 
phosphatidylinositol 4,5-bisphosphate (PIP2).  PIP2 directly binds to β-ENaC and 
increases the open probability state [12]. Airway epithelial cells also express the Calcium 
(Ca2+)-activated Cl- channel (CaCC).  CaCC is activated in response to an elevation in 
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intracellular Ca2+.  When activated, CaCC secretes Cl- and may be able to regulate the 
ASL [13-15]. 
 Under normal physiological conditions, PCL height is maintained at ~7 μm [9, 14, 
16, 17].  This is the optimal height for mucociliary clearance, because outstretched cilia 
tend to measure 7 μm [16].  These PCL height measurements were performed in vitro, 
but it is reasonable to assume that similar PCL heights would occur in vivo.   Conversely, 
the mucus layer height varies considerably, with in vivo measurements ranging from 7 to 
70 μm [14].  In the event that PCL height decreases, the airway epithelium will respond 
to increase the height back to 7 μm.   This is achieved by stimulating a G-protein 
coupled receptor (GPCR) with the nucleotide adenosine (ADO) to activate adenylyl 
cyclase.  Adenylyl cyclase raises intracellular cAMP levels, which ultimately activates 
CFTR to secrete Cl- and raise PCL height [9, 14, 16].  Activation of CFTR also inhibits 
ENaC through an unknown mechanism to decrease Na+ absorption [18]. Conversely, if 
the PCL contains excess fluid and height is elevated, the epithelial cells respond by 
transporting extracellular Na+ into the cell via ENaC.  Excess fluid likely decreases CFTR 
activity by lower the concentration of ADO in the ASL.  As a result, ENaC activity 
increases and excess water is removed to lower PCL height [17].  PCL/ASL hydration is 
a regulation balancing act.  If ion transport is obstructed, the ASL can dehydrate, which 
can disrupt MCC.  This situation occurs in the genetic disease cystic fibrosis, which will 
be addressed in detail in a subsequent section. 
 
1.3 Calcium Signaling 
Calcium is one of the most important second messengers in a cell and regulates 
a wide variety of cellular functions including muscle contraction, cell differentiation and 
proliferation, and apoptosis [19].  Therefore, regulating cytosolic Ca2+ levels is critical for 
maintaining cellular health under diverse circumstances.  This is achieved by 
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sequestering Ca2+ to internal stores and by regulating the influx of extracellular Ca2+ [20].  
The endoplasmic reticulum (ER) is one of the primary intracellular Ca2+ stores and 
actively internalizes cytoplasmic Ca2+ through the Sarco/Endoplasmic Reticulum 
Calcium transport ATPase (SERCA) pump.  When a cell is under resting conditions, 
there is a constant leakage of Ca2+ from the ER, which is then transported back into the 
ER via the SERCA pump to control cytoplasmic Ca2+ levels [21-23].  This leakage of 
Ca2+ from the ER can be easily exploited to deplete ER Ca2+ with a drug called 
thapsigargin [21].  Thapsigargin is a SERCA pump inhibitor, which prevents the transport 
of Ca2+ into the ER.  Thus, in the presence of thapsigargin, ER Ca2+ can be depleted 
without signaling through a GPCR. 
Mobilization of ER Ca2+ typically occurs following a GPCR-mediated signaling 
event on the cell surface (Fig. 1.2).  Airway epithelial cells express the P2-purinergic 
receptor, P2Y2, which can be activated by both adenosine triphosphate (ATP) and 
uridine triphosphate (UTP).  Both of these nucleotides are constantly released from the 
airway epithelium, but are metabolized by ectonucleotidases to establish a steady-state 
nucleotide concentration.  However, mechanical stimulation, such as coughing, can 
increase nucleotide concentrations.   ATP and UTP can then act in an autocrine manner 
to induce a signaling cascade.   P2Y2 is coupled to Gq, which activates phospholipase C 
(PLC).  PLC converts phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-
triphosphate (IP3) and diacyl glycerol (DAG).  IP3 then diffuses through the cytosol to the 
ER where it activates the IP3 receptor (IP3-R) to induce the release of Ca
2+.  Following 
ER Ca2+ depletion, a process known as store-operated Ca2+ entry (SOCE) occurs, 
whereby extracellular Ca2+ is brought into the cell to continue propagating a signaling 
cascade and replenish depleted stores [24, 25]. 
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1.4 Store-Operated Calcium Entry 
SOCE was first described in 1989 [20, 26] and has been extensively studied 
subsequently.  Shortly after the discovery of SOCE, a membrane current known as the 
Ca2+ release-activated Ca2+ current (ICRAC) was identified [27].  ICRAC has been the most 
studied aspect of SOCE, but it wasn’t until after the year 2000 that the key signaling 
elements leading up to ICRAC were discovered [28, 29].  It is now understood that SOCE 
and ICRAC require two protein families: the stromal interaction molecule (STIM) proteins 
(STIM1 and STIM2) and the Orai proteins (Orai1, Orai2, and Orai3).  The STIM proteins 
are Ca2+ sensing proteins that span the membrane of the ER and Orai proteins are the 
pore-forming subunit of the CRAC channel [30].   
In addition to Orai, members of the transient receptor potential (TRP) superfamily 
have long been thought of as store-operated channels (SOCs).  However, only Orai1 
has been proven to conduct ICRAC [29, 31].  The TRPC (Canonical; TRPC1-TRPC7) 
family within the TRP superfamily has been extensively studied.  Overexpression of 
TRPC1 and 4 have been shown to increase store-operated entry [32-34], while 
knockdown of TRPC1 and 4 with siRNA significantly decreased store-operated entry in 
multiple cell lines [33, 35-37].  This suggests that TRP channels play a major role in 
SOCE.  However, there is considerable evidence that TRP channels are not the main 
subunits of SOCs.  In Drosophila, TRP channels have been shown to be receptor-
operated channels, instead of store-operated channels [38-40].  Also, the ion selectivity 
of TRP channels is different from the selectivity observed in ICRAC [41].  The exact role 
TRP channels play in SOCE is not fully understood.  However, it is possible that they 
may mediate several Ca2+ signaling mechanisms.  TRPC3 has been shown to enter into 
a macromolecular complex with STIM1 and Orai1 after Ca2+ depletion [42].  Additionally, 
Orai1 can interact with a TRPC1/4 complex endogenously expressed in endothelial cells 
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to modulate ion permeability [43].  Thus, additional experiments need to be performed in 
order to better understand this process. 
 
1.5 STIM1 
The STIM proteins are ubiquitously expressed in vertebrates [44].  STIM1 
expression is generally higher than STIM2 expression [44], except in the brain where 
STIM2 predominates [45].  The essential role of STIM1 in SOCE was initially discovered 
in Drosophila S2 cells after RNAi-mediated knockdown of Drosophila Stim significantly 
reduced SOCE [46].  Since then, human STIM1 has been shown to be essential for 
SOCE [47].  Conversely, the exact role of STIM2 in SOCE is not fully understood.  
However, there is mounting evidence that STIM2 may be important for maintaining 
resting cytosolic Ca2+ homeostasis and ER Ca2+ levels, rather than a role in SOCE [48-
51].    
 Structurally, human STIM1 is a 685 amino acid protein that contains a single 
transmembrane pass (Fig. 1.3).  The N-terminal domain of STIM1 resides in the ER 
lumen, while the larger C-terminal domain resides in the cytoplasm.  The N-terminus 
contains two distinct domains: an EF-hand, which senses changes in ER Ca2+, and a 
sterile alpha motif (SAM) domain, which mediates oligomerization.  The C-terminus of 
STIM1 is comprised of several domains.  Following the transmembrane domain are two 
coiled-coil domains that contain the STIM1-Orai1 activation region (SOAR), which is 
followed by the serine-proline (S/P) rich region, and the lysine rich region.  The C-
terminus of STIM1 also contains an ezrin-radixin-moesin (ERM) domain that 
encompasses the coiled-coils and the SOAR domain.  STIM1 is also known to associate 
with microtubules by binding the microtubule plus-end surfing protein EB1 [52].  Under 
resting conditions, STIM1 is localized throughout the ER (Fig. 1.2).  However, after ER 
Ca2+ is depleted, STIM1 undergoes a conformational change that induces puncta 
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formation and translocation to the ER-plasma membrane junction where it induces the 
influx of Ca2+ through Orai1.  Initially, STIM1 was thought to traffic from the ER to the 
plasma membrane where it induced extracellular Ca2+ influx [53, 54].  However, multiple 
studies have since shown that SOCE only requires STIM1 that is localized to the ER [47, 
55, 56].   
 This entire process has been extensively studied and the role that each domain 
of STIM1 plays is now becoming clearer.  Arguably, the most important domain is the 
EF-hand, which senses Ca2+ depletion.  The STIM1 EF-hand binds Ca2+ with unusually 
low affinity and has a dissociation constant (Kd) of ~0.2-0.6 mM [57].   The ER lumen of 
eukaryotes are predicted to contain ~0.2-2 mM free Ca2+ [57].  This high level of lumenal 
ER Ca2+ may help explain why the EF-hand binds Ca2+ with low affinity, since the main 
of role STIM1 as an ER Ca2+ sensor is to induce the influx of extracellular Ca2+ when ER 
levels fall.  It is physiologically beneficial for the cell to sense minor depletions in ER 
Ca2+ to ensure that enough Ca2+ is stored for a myriad of signaling events.  Upon ER 
Ca2+ depletion, the EF-hand and nearby SAM domain undergo conformational changes 
that promote oligomerization of multiple STIM1 proteins.  Oligomerization is completely 
dependent on N-terminal interactions.  Previous studies have shown that the N-terminus 
of STIM1 is capable of self-assembling into oligomers, indicating that oligomerization of 
the EF-SAM domains initiates SOCE [57, 58].   
Multiple studies have addressed the mechanism utilized by STIM1 to redistribute 
to the plasma membrane.  The N-terminus of STIM1 contains a poly-basic, lysine rich 
region that may be involved in STIM1 redistribution.  In the absence of Orai1, removing 
the lysine rich region prevents STIM1 oligomers from localizing to the plasma membrane 
[59, 60].  However, when Orai1 is co-expressed, truncated STIM1 is able to target to the 
ER-plasma membrane junction [60].  This suggests that multiple mechanisms are 
utilized by STIM1 for targeting to the plasma membrane.  It has also been suggested 
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that the cytoskeleton may play a role in STIM1 redistribution [61].  Under resting 
conditions, STIM1 is known to co-localize with α-tubulin, taking on a tubular appearance 
similar to the microtubule network [61].  The tubular appearance of STIM1 can be 
abolished by depolymerizing the microtubule network with nocodazole, which forces 
STIM1 to take on an ER distribution pattern.  There have been conflicting reports on 
whether STIM1 association with microtubules is important for SOCE.  Initial studies 
suggested that disrupting the microtubule network inhibited ICRAC after ER Ca
2+ depletion 
[61].  However, others have addressed the same issue and have concluded that 
disrupting the microtubule network does not inhibit SOCE [52, 62, 63].  It is now 
understood that STIM1 interacts with microtubules through the microtubule-plus-end 
tracking protein EB1 [52].  When ER Ca2+ stores are full, STIM1 appears as comets that 
track the growing ends of microtubules.  This association is believed to be important for 
remodeling the ER and may play a role in ER Ca2+ uptake [52].   
 
1.6 STIM1 Phosphorylation 
In recent years, extensive research has been conducted to investigate the role of 
phosphorylation on STIM1 function.  The C-terminus of STIM1 contains the S/P rich 
region that contains several serine residues that are targets for phosphorylation [64, 65].  
However, additional phosphorylation sites outside of this region have been identified [64, 
66].  It now appears that the functional impact of phosphorylation wholly depends on the 
site and can be employed to both enable and inhibit SOCE [64-67]. 
 A study from 2009 identified several serine phosphorylation sites that are 
permissive for STIM1 function and for inducing SOCE [64].  Specifically, Serine (Ser) 
575, Ser 608, and Ser 621 were identified as ERK1/2 phosphorylation sites.  Utilizing 
mass spectrometry, the authors observed little variation in the phosphorylation status of 
these sites after ER Ca2+ depletion.  However, ERK1/2 phosphorylation, which is an 
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indicator of ERK1/2 activity, was significantly increased after ER Ca2+ depletion.  
Additionally, they observed a significant increase in phosphorylation of 
immunoprecipitated STIM1 after ER Ca2+ depletion.  Importantly, STIM1 phosphorylation 
was abolished when all three serine phosphorylation sites were mutated to alanines, 
which was associated with a decrease in SOCE in cells expressing the triple point 
mutant.  Taken together, the authors concluded that STIM1 phosphorylation on Ser 575, 
Ser 608, and Ser 621 was required to activate SOCE [64]. 
 STIM1 phosphorylation has also been shown to inhibit SOCE.  It has been 
documented extensively that SOCE is strongly inhibited during mitosis [68-72].  
However, the underlying mechanism had never been identified.  In a recent study, 
researchers discovered that STIM1 phosphorylation strongly increased during mitosis, 
as indicated by a phospho-specific antibody.  They specifically identified Ser 486 and 
Ser 668 as STIM1 phosphorylation sites that inhibit SOCE during mitosis [65].  
Consequently, STIM1 was excluded from the mitotic spindle during mitosis, because 
phosphorylation of STIM1 disrupted binding to the microtubule plus-end tracking protein 
EB1 [67].  Mutation of the STIM1 phosphorylation sites to alanines prevented EB1 
dissociation and STIM1, along with the ER, redistributed to the mitotic spindle.  
However, the functional significance of disrupting STIM1-EB1 dissociation during mitosis 
is unknown [67]. 
 STIM1 has also been shown to undergo tyrosine phosphorylation.  A recent 
study immunoprecipitated STIM1 from platelets and found that after depleting ER Ca2+ 
with thapsigargin, STIM1 was rapidly phosphorylated on tryosine residues as indicated 
by a phospho-tyrosine specific antibody [66].  Additionally, blocking tyrosine 
phosphorylation with SKI-606, a Src tyrosine kinase inhibitor, decreased the STIM1-
Orai1 interaction [66].  However, the authors of this study did not conduct additional 
studies to specifically determine which tyrosine residue was phosphorylated and whether 
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it was essential for SOCE in platelets.  Thus, the exact role tyrosine phosphorylation 
plays in STIM1 function and SOCE remains to be determined. 
 
1.7 Orai1 
Orai1 is 301 amino acids in length and is predicted to contain four 
transmembrane domains with the N- and C-termini located within the cytoplasm [73].  
The N-terminus of Orai1 contains a proline/arginine rich region, while the C-terminus 
contains a putative coiled-coil that is conserved between Orai family members [74, 75].  
Orai1 localizes to the plasma membrane and exists as dimer under resting conditions 
[76].  Following ER Ca2+ depletion and redistribution of STIM1 to the ER-plasma 
membrane, Orai1 clusters with STIM1 into puncta [76].  Several studies have shown that 
Orai1 dimers oligomerize into tetramers following ER Ca2+ depletion [76-78].  Moreover, 
it has been suggested that Orai1 tetramers interact with two STIM1 molecules to form 
the functional CRAC channel [77].  However, others have proposed the formation of 
higher order oligomers [79].  The recently determined crystal structure of Orai from 
Drosophila melanogaster indicated that Orai assembles into a hexamer [80].   
Structural studies have also shown that the first transmembrane segment in each 
Orai1 subunit forms the ion pore [79-81].  Amino acids lining the pore strongly select for 
Ca2+ and do not allow the passage of other divalent cations, such as Ba2+ and Cd2+.  
Furthermore, Orai1 selectivity for Ca2+ is 1000 times greater than selectivity for 
monovalent cations, such as Na+ and K+ [80, 82].  However, if Ca2+ is removed from the 
extracellular media, Orai1 becomes permeable to monovalent cations [80, 83].  The third 
transmembrane segment, while not lining the pore, has also been shown to be involved 
in permeability and gating [84].  Orai1 is an inward rectifier and even at positive voltages 
does not conduct current outwardly.  However, a recent study showed that mutating key 
residues within the third transmembrane segment disrupted this characteristic.  The 
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mutant Orai1 was able to conduct a large current at positive voltages and was 
constitutively active, even in the absence of STIM1.   It is believed that the third 
transmembrane segment is in a conformation that places negatively charged residues 
near Orai1’s selectivity filter that facilitates inward Ca2+ current.  Furthermore, the third 
transmembrane segment may also stabilize Orai1’s closed state [84].  
 
1.8 STIM1-Mediated Regulation of Orai1 
Whether STIM1 directly interacts with Orai1 has remained controversial.  In 
multiple studies, Förster resonance energy transfer (FRET) has been utilized to study 
the STIM1-Orai1 interaction [85-87]. There is little FRET between STIM1 and Orai1 
under resting conditions.  However, there is a significant increase in FRET after ER Ca2+ 
depletion [85-87].  Additionally, STIM1 has been shown to co-immunoprecipitate with 
Orai1 [66, 88].  These results suggest that STIM1 and Orai1 are interacting.  However, 
FRET only indicates proximity between two proteins and does not prove an interaction.  
While co-immunoprecipitation experiments do prove an interaction, they cannot 
distinguish between a direct or indirect interaction.   
However, evidence suggesting a direct interaction between STIM1 and Orai1 is 
mounting.  A minimal sequence in the C-terminus of STIM1 was recently identified as 
being sufficient to activate Orai1 [60, 89-91].  This region is known as the SOAR domain 
(amino acids (aa) 344-442), which is located within the ERM domain and encompasses 
the second coiled-coil [91].  Studies published in parallel also identified the SOAR 
domain, with slight variations, and was alternatively termed CAD (CRAC activation 
domain (aa 342-446)) [60]; CCb9 (coiled-coil domain containing region b9 (aa 339-444)) 
[89]; and OASF (Orai1 activating small fragment (aa 233-450)) [90].  When the SOAR 
domain alone was expressed in HEK293 cells it was preferential localized near the 
plasma membrane, suggesting that Orai1 may play a role in targeting STIM1 to the 
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plasma membrane [91].  Mutating the SOAR domain prevents activation of Orai1; 
however, it does not disrupt STIM1-Orai1 co-clustering [60, 91], which indicates that co-
clustering alone is not sufficient to activate Orai1, implying the existence of another 
regulatory mechanism.   
Furthermore, the C-terminus of Orai1 contains a coiled-coil that has been shown 
to be essential for the STIM1-Orai1 interaction.  Studies have shown that mutating a 
single leucine (aa 273) within the coiled-coil of Orai1 was sufficient to disrupt signaling 
[74, 75].  The mutant Orai1 was unable to interact and co-cluster with STIM1 and 
remained inactive following ER Ca2+ depletion [74, 75].  Details regarding the role of 
Orai1’s N-terminus are also becoming apparent.  A recent study suggested STIM1 
activates Orai1 in a stepwise manner [92].   The authors of this study proposed that 
STIM1 initially binds the C-terminus of Orai1, which enables STIM1 to bind the N-
terminus of Orai1 and induces a conformational change [92].  Taken together, it is now 
apparent that STIM1 and Ora1 directly interact and this interaction is dependent on 
specific sequences in both STIM1 and Orai1. 
 
1.9 CaCCs 
 CaCCs were first identified over 30 years ago when researchers observed a 
Ca2+-dependent Cl- current in the rabbit colon [93].  Since then, CaCCs have been 
identified in almost every tissue and cell type [94-96].  CaCCs have been shown to play 
essential roles in many physiological processes, including secretion of fluid from 
epithelial cells, regulating smooth muscle contraction, olfactory signal transduction, 
phototransduction, and action potentials in neurons [95, 97].   
With low cytoplasmic Ca2+ levels, CaCCs are inactive, but can be activated by 
elevating intracellular Ca2+ to the 0.2-1.0 µM range [96, 98].  CaCCs are also voltage 
sensitive [96, 99].  In the absence of Ca2+, membrane potential alone is not sufficient to 
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activate CaCC.  However, with the addition of a permissible amount of Ca2+, a 
membrane depolarization will further increase CaCC activity.  At high concentrations of 
intracellular Ca2+, CaCC is fully activated and a change in the membrane potential will 
not further modulate activity [96, 99].  
Despite numerous studies on functional CaCC activity, the molecular subunit of 
the channel remained unknown until recently.  Numerous proteins were proposed as 
potential CaCCs, such as CLCA [100], bestrophins [101, 102], and tweety [103].  
However, when expressed in cells, the electrophysiological properties generated by 
these proteins did not match the classical CaCC characteristics, such as outward 
rectification and voltage sensitivity [104], suggesting that the true CaCC subunit had not 
yet been discovered.  It wasn’t until 2008, when three laboratories independently 
identified Anoctamin 1 (Ano1)/transmembrane protein 16A (TMEM16A) as CaCC [105-
107]. 
 The three laboratories that simultaneously identified Ano1 utilized different 
techniques that all lead to the conclusion that Ano1 is CaCC. (i) Caputo and colleagues 
used a functional genomics approach to identify Ano1 [105].  It was previously observed 
that IL-4 exposure upregulated Ca2+-dependent Cl- secretion in human bronchial 
epithelial cells (HBECs).  Therefore, they performed microarray analysis to identify 
genes with unknown functions that were upregulated in HBECs after IL-4 exposure, 
which lead them to Ano1.  (ii) Schroeder and colleagues performed expression cloning 
to identify Ano1 [106].  This technique utilizes a collection of coding sequences that are 
obtained from cells that express high levels of a specific ion channel.  This collection 
was then expressed in salamander oocytes, which do not endogenously express CaCC, 
to identify the specific protein that matched the electrophysiological properties of CaCC 
[106].  Finally, (iii) Yang and colleagues identified Ano1 by searching public databases to 
identify channels or transporters that contain more than two transmembrane domains.  
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Through various overexpression and siRNA knockdown experiments they identified 
Ano1 and concluded that it is the subunit of CaCC [107].   
 
1.10 The Anoctamin Family 
 The Anoctamin family of proteins contains 10 members with Ano1 being the most 
frequently studied.  All eukaryotes express Anoctamin proteins [108].  However, only 
higher order eukaryotes, such as mammals, express all 10 members.  In mammals, 
Ano1 and 2 are closely related with a sequence homology of ~60% [97].   There is 
significant sequence variability between Ano1 or 2 and other family members, 
suggesting a possible divergence in function [109].  Only Ano1, Ano2, and Ano6 have 
been shown to form Cl- channels [105-107, 110, 111].  There have been conflicting 
reports describing cellular localization of the other family members.  Tian et al. found that 
all Anoctamin family members except Ano8, 9, and 10 reach the plasma membrane in 
HEK293 and FRT cells [112].  Additionally, previous reports have suggested that Ano5 
and 7 can reach the plasma membrane [113, 114].  Conversely, a recent study from 
Duran et al. found no surface expression of Ano3-7 in HEK293 cells and they did not 
generate Cl- currents when tested by whole cell patch clamping [115].  They went on to 
speculate that Ano3-7 may reside in intracellular organelles, such as the ER, but it is 
unclear whether they are actually CaCCs.   
  
1.11 Ano1 Structure and Function 
Structurally, Ano1 is unique and is not similar to any other protein with a known 
function, including other ion channels.  Ano1 is predicted to contain 8 transmembrane 
domains with the N- and C-termini protruding into the cytosol (Fig. 1.4).  It has also been 
proposed that there is a re-entrant loop between transmembrane domains 5 and 6 that 
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may be involved in gating [107].  However, a recent study suggested that the predicted 
model may not be completely accurate [116].  The authors of this study proposed that 
the fourth extracellular loop is actually intracellular and may contain a Ca2+-binding site.  
Their model still predicted the presence of a re-entrant loop; however they suggest that it 
is located between transmembrane domains 6 and 7 [116]. 
Interestingly, the gene encoding Ano1 can be alternatively spliced to generate 
several Ano1 isoforms (Fig 1.4) [117].  Ano1 contains four alternative segments dubbed 
a, b, c, and d.  Segments a and b are located in the N-terminus of Ano1 while the c and 
d segments are in the first cytoplasmic loop.  The alternative splicing pattern of Ano1 
varies across human tissues and organs.  Some tissues express multiple Ano1 isoforms, 
while other tissues exclusively express a single isoform [117].  Alternative splicing has 
also been shown to impact function.  For example, inclusion of segment b decreases 
Ca2+ affinity, which translates to a decrease in channel activity when analyzed by patch-
clamping.  Furthermore, the currents generated in cells expressing the ac-Ano1 variant 
are much larger than those seen in cells expressing abc-Ano1 [117].  This suggests that 
alternative splicing is a mechanism that can be exploited to regulate channel properties, 
such as Ca2+ sensitivity. 
While it is known that Ano1 is activated by Ca2+, the protein itself does not 
contain any known canonical Ca2+ binding domains.  This suggests that Ano1 may 
contain a novel Ca2+ binding domain or that an accessory protein confers Ca2+ 
sensitivity.  The first intracellular loop of Ano1 contains a series of positively charged 
glutamic acids that resemble the “Ca2+ bowl”, which was first observed in the BK channel 
and can directly bind Ca2+ [118].  However, in a recent study it was suggested that the 
series of glutamic acids in the first intracellular loop may be important for sensing voltage 
and not Ca2+ [119].  The authors provided evidence that the four adjacent amino acids in 
the first intracellular loop, which are actually the c splice variant segment, are required 
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for sensing Ca2+ [119].  To date, all human tissues examined that express Ano1 contain 
the c splice variant segment, suggesting that this segment is essential for function.  
However, the ab-Ano1 splice variant is still functional, but has different 
electrophysiological properties than abc-Ano1 [117]. Outward rectification is a 
characteristic of abc-Ano1, but this property is abolished when the c segment is 
removed.    Furthermore, the ab-Ano1 splice variant is able to generate large currents at 
both negative and positive membrane potentials in the presence of a permissible amount 
of Ca2+ [117]. 
Alternatively, it has been suggested that Ano1 does not directly sense Ca2+, but 
is mediated through an ancillary protein.  A study from 2011 suggested that Ano1 
physically interacts with the Ca2+ binding protein calmodulin and that this interaction 
controls Ano1 function [120].  The authors of this study provided evidence that 
calmodulin interacts with the N-terminus of Ano1 on a sequence that overlaps with the b 
splice variant region.  However, they noted that the ac-Ano1 splice variant, which lacks 
the b segment, was still activated by a rise in intracellular Ca2+, though not to the same 
extent as the abc-Ano1 splice variant [120].  This is in direct conflict with previously 
published data that suggested that the ac-Ano1 splice variant is more Ca2+ sensitive 
[117].   
Ano1 is present in the plasma membrane.  However, little is known about the 
trafficking or protein interactions of Ano1.  To better understand this process, a group 
purified Ano1 from HEK cells and performed mass spectroscopy to identify Ano1’s 
interactome [121].  This process identified hundreds of binding partners, including the 
ERM proteins: ezrin, radixin, and moesin, which are associated with the actin 
cytoskeleton.  Notably, calmodulin failed to pull down with Ano1.  The ERM proteins 
were found to strongly co-localize with Ano1 at the plasma membrane in HEK cells and 
mouse salivary glands.  Importantly, knockdown of moesin inhibited Ano1 activity as 
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indicated by whole-cell patch clamping.  Overall, their data suggests that the ERM 
proteins and potentially other regulatory proteins associated with the actin cytoskeleton 
may be involved in regulating Ano1 gating, trafficking, or organizing Ano1 into a 
signaling network [121].    
Together, it is now apparent that regulation of Ano1 is more complex than 
originally thought and that multiple mechanisms may be utilized.  Alternative splicing 
appears to add another layer of complexity and may account for the diverse 
characteristics of Ano1 that have been observed in various tissues [96].    
 
1.12 Cystic Fibrosis 
Cystic fibrosis (CF) is an autosomal recessive genetic disease that affects 
multiple organs, including the liver, pancreas, reproductive tract, and the lungs.  CF is 
characterized by an inability to properly regulate ion transport, especially Cl-, across 
epithelia.   CF is caused by mutations in the cftr gene and as a result, CFTR-mediated 
Cl- secretion is disrupted.  There are five classes that CFTR mutations generally fall into: 
(i) defective synthesis, (ii) defective processing, (iii) defective regulation, (iv) defective 
ion transport, and (v) reduced cell surface abundance [122-124].  More than 1400 
mutations in CFTR have been identified.  However, by far the most common mutation in 
humans is ΔF508, which accounts for over 70% of all CFTR mutations [125].  In the 
lungs, the loss of CFTR-mediated Cl- secretion disrupts ASL regulation.  The absence of 
CFTR also upregulates ENaC, leading to Na+ hyperabsorption [126, 127].  As a result, 
the ASL dehydrates and proteins in the mucus layer concentrate, which collapses the 
cilia, impairing MCC [127, 128] (Fig. 1.1).  Goblet cells continue to release mucins into 
the airways, which eventually form plugs that block air flow and impede respiration [129].  
Obstruction of the airways ultimately results in chronic infection, inflammation, and 
destruction of the lung [129].   
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While patients with CF lack CFTR, they retain expression of CaCC.  CaCC may 
preserve ASL hydration, at least until a catastrophic event, such as an infection, occurs 
that decreases CaCC activity [13-15, 130].  It is for this reason that CaCC has attracted 
attention as a pharmacological target.  CaCC is activated in response to an elevation in 
intracellular Ca2+, which is achieved by stimulating P2Y2 with ATP or UTP.  This also 
inhibits ENaC due to a reduction in PIP2 levels.  However, both ATP and UTP are readily 
broken down by ectonucleotidases residing on the cell surface, undergoing rounds of 
hydrolysis until only inosine remains [131].  Pharmacological agents have been 
developed that are hydrolysis-resistant and longer lived than ATP and UTP to increase 
CaCC mediated Cl- secretion [132].  However, they have not proven to be effective in 
clinical trials [132].  Therefore, it would be beneficial to develop compounds that can 
directly target and activate CaCC. 
 
1.13 Sex Differences in Airway Diseases 
It has been extensively documented that sex can greatly affect lung health and 
disease.  Several studies have shown that female CF patients suffer more severely than 
their male counterparts.  The incidence of CF is not sex linked [133].  However, females 
have a significantly higher mortality, a shorter life span, and exhibit an increased rate of 
lung function decline [134, 135].  Recent studies have shown that acute exacerbations, 
i.e. a sudden decline in lung function, are cyclical and track the menstrual cycle [136].  
Specifically, female CF patients are most at risk of experiencing an acute exacerbation 
when blood estrogen levels are elevated, during the peri-ovulatory phase.  This risk 
significantly decreases once estrogen levels decline.   
Most CF patients acquire Pseudomonas aeruginosa at some point in their 
lifetime.  However, female CF patients tend to acquire it earlier in life than males [134].  
Despite intense antibiotic treatments, P. aeruginosa infections endure, likely due to 
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increased antibiotic resistance.  Eventually P. aeruginosa will undergo mucoid 
conversion, which is characterized by excessive production of alginate that surrounds 
and protects the bacteria.  Biofilms are extremely resistant to antibiotics and will persist 
indefinitely.  The process of mucoid conversion has been shown to be affected by 
estrogen.  Elevations in estrogen increase alginate production and promote biofilm 
formation [136].  CF females may also be inherently prone to infection.  Estrogen has 
been shown to upregulate production of secretory leucoprotease inhibitor (SLPI), which 
inhibits interleukin-8 (IL-8) and could prevent an immune response to a pathogen [137].    
Occurrence and prognosis of asthma has also been shown to be affected by sex 
differences.  During the prepubescent period, boys are twice as likely to develop asthma 
as girls [138].  This discrepancy may be due to developmental differences between boys 
and girls rather than sex hormones.  Male airway growth is slower than that in females, 
suggesting that boys are inherently more at risk of developing asthma than girls [139, 
140].  However, after puberty, there are approximately twice as many women with 
asthma than men [138, 141].  It was initially thought that the discrepancy switch after 
puberty from males to females in asthma was partially due to airway size and growth, 
because adult females have smaller lungs and airways than males [142].  However, it is 
now understood that this discrepancy is most likely due to differences in sex hormones, 
because girls that underwent early menarche are twice as likely to develop adult asthma 
as girls that underwent menarche later [143].  Additionally, the menstrual cycle has been 
shown to greatly influence the symptoms of asthma.  During the luteal phase of the 
menstrual cycle, when there are large fluctuations in estrogen and progesterone levels, 
roughly 40% of women with asthma experience changes in the severity of their asthma 
[144, 145].  A hallmark characteristic of asthma is bronchoconstriction, which is caused 
by contraction of airway smooth muscle (ASM).  ASM contraction is dependent on Ca2+ 
that is released from the sarcoplasmic reticulum upon stimulation.  Estrogen has been 
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shown to act as a bronchodilator in human ASM cells by decreasing intracellular Ca2+ 
levels [146], suggesting that estrogen may be airway protective in asthma.  However, 
there are many other characteristics of asthma that may be affected by estrogen, 
including ASM hyperplasia and hypertrophy, goblet cell hyperplasia, and inflammation.   
Chronic obstructive pulmonary disease (COPD) also disproportionately affects 
women [142].  Dyspnea, or shortness of breath, is the main characteristic of COPD and 
is due to emphysema and narrowing of the airways.  Historically, COPD was considered 
a male disease that was a result of smoking.  However, the number of COPD cases in 
women has been increasing and now equals those in men [142, 147].  Additionally, the 
number of deaths attributed to COPD is now greater in women than in men [147].  There 
are numerous factors that could be involved in this discrepancy, including the effect of 
smoking on female airways.  Research has shown that women are more susceptible to 
the adverse effects of cigarette smoke [147, 148].  However, in non-smokers, nearly 
80% of early onset COPD cases were found to occur in women [149].  Thus, there are 
likely sex specific factors that affect COPD.   
Occurrence and prognosis of lung cancer may also be affected by sex hormones.  
More women are killed every year by lung cancer than ovarian, uterine, and breast 
cancer combined [150].  The number of lung cancer cases continues to climb in women, 
while in men the number of cases is declining.  This may be partially due to smoking 
habits, because the number of female smokers peaked later than that seen in males 
[151].  Additionally, it has been suggested that women are more susceptible to cigarette 
smoke [152].  However, in nonsmokers, studies have shown that women are three times 
more likely to be diagnosed with lung cancer than men [153, 154].  This suggests that 
exposure to sex hormones may be a risk factor.  The majority of women diagnosed with 
lung cancer are diagnosed with adenocarcinoma (a type of non-small cell lung 
carcinoma), which is also the leading type of lung cancer seen in nonsmokers [152, 155, 
21 
 
156].  Additionally, women who have longer reproductive periods are at an increased 
risk of adenocarcinoma [157].  In women that are diagnosed with adenocarcinoma, a 
higher level of circulating estrogen has been associated with shorter survival [158].   
 
1.14 Estrogen Receptors 
 There are three known estrogen receptors: estrogen receptor alpha (ESR1), 
estrogen receptor beta (ESR2), and G-protein coupled receptor 30 (GPR30).  ESR1 and 
ESR2 are the classical estrogen receptors that translocate from the cytoplasm to the 
nucleus upon activation where they act as transcription factors [159].  Upon binding 
estrogen, the receptor dimerizes and binds to an estrogen response element in the 
nucleus.  Co-activator proteins are then recruited and gene transcription is initiated 
[159]. GPR30, on the other hand, is a GPCR that does not translocate to the nucleus 
[160].  GPR30 resides in both the plasma membrane and intracellular compartments.  
When stimulated, GPR30 can activate many different signaling cascades [161].   
While the canonical estrogen receptors (ESR1 and ESR2) are generally 
regarded as regulators of gene transcription, it has been shown that they can also signal 
in a non-genomic fashion [159, 162].  It is believed that a small pool of these receptors 
resides in the cytoplasm and in the plasma membrane [159, 163].  Signaling through 
these receptors is rapid and can initiate several signaling cascades, such as the 
MAPK/ERK and PI3K/Akt cascades [162, 164].  The mechanism utilized by canonical 
estrogen receptors for non-genomic signaling is not fully understood.  However, there is 
evidence that estrogen receptors can interact with G-proteins, as indicated through co-
immunoprecipitation assays [163].  Direct interactions between estrogen receptors and 
other proteins, such as Shc, Src, and p85, the subunit of PI3K, have also been 
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described [165, 166].  This suggests estrogen receptors do much more than regulate 
gene transcription and may play an important role in cell function and health. 
 
1.15 Estrogen Inhibits CaCC 
 A previous publication from the Tarran lab determined that acute exposure to 
estrogen can inhibit CaCC in the airways [167].  Nasal potential differences were 
performed to measure CaCC activity in vivo.   Elevated levels of circulating estrogen 
corresponded with a decrease in CaCC activity, while CFTR and ENaC were unaffected.  
While CF airways lack CFTR, they still retain the ability to partially regulate ASL height 
through CaCC.  Normal tidal breathing causes ATP to be released from the epithelia that 
induces the SOCE pathway and ultimately activates CaCC.  To test whether estrogen 
inhibits CaCC by impacting the SOCE pathway, they performed Ca2+ imaging studies.  
They specifically observed a decrease in the influx of Ca2+, while ER Ca2+ was 
unaffected.  Furthermore, Ussing chamber experiments confirmed that estrogen was not 
directly impacting CaCC.  Exposing HBECs to ionomycin, which bypasses the SOCE 
pathway to directly increase [Ca2+]i, had no effect on CaCC activity, while the UTP 
response was significantly inhibited.  Also, only cells expressing ESR1 were affected, 
while those expressing ESR2 showed no decreases in Ca2+ influx.  Physiologically, this 
corresponds with a decrease in ASL height.  Therefore, in female patients with CF, 
losing CaCC mediated Cl- secretion during peak estrogen levels may have detrimental 
consequences.   
 Taken together, these data establish a sex specific model describing estrogen-
mediated inhibition of CaCC (Fig. 1.5).  In normal males and females, CFTR is present 
and is the main regulator of ASL hydration.  However, CaCC is also present and 
contributes to ASL regulation.  When estrogen levels are elevated in females, CaCC 
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activity is decreased.  Nevertheless, CFTR is still present and ASL hydration is not 
affected.  In patients with CF, who lack CFTR, CaCC represents the only Cl- channel 
that can regulate the ASL.  While the ASL in CF males is ultimately dehydrated due to 
Na+ hyperabsorption, the presence of CaCC may help alleviate or delay some of the 
symptoms associated with CF.  However, in CF females, estrogen-mediated inhibition of 
CaCC may leave them at a distinct disadvantage.  This may help explain why CF 
females suffer more severely and have a shorter life span than CF males. 
 
1.16 Goals and Hypotheses tested by the studies presented in this 
dissertation 
The aim of the studies presented in this dissertation was to contribute to the 
understanding of the physical and functional aspects of the CaCC subunit Ano1.   It was 
not until recently that Ano1 was identified as an essential subunit of CaCC [105-107], so 
very little is known about the structure and function of the channel.  In order to fully 
understand how Ano1 functions it is first necessary to know whether Ano1 oligomerizes.  
Therefore, in Chapter 2, we sought to test the hypothesis that Ano1 exists as an 
oligomer.  We utilized a combination of biochemical and microscopy based assays to 
examine the quaternary structure of Ano1.   
In the airways, sex differences are known to impact lung health.  CaCC activity is 
inhibited by elevated levels of circulating estrogen, which may be detrimental to female 
CF patients [167].  Previous work from the Tarran lab demonstrated that estrogen 
inhibited CaCC indirectly by reducing extracellular Ca2+ influx [167].  Thus, in Chapter 3, 
we tested the hypothesis that estrogen inhibits upstream signaling components of the 
SOCE pathway to block CaCC activity.  Because STIM1 and Orai1 are important 
components of the SOCE pathway, we focused our attention on how estrogen could 
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impact their function.  We propose three distinct mechanisms that could be utilized by 
estrogen to disrupt SOCE.  Acute exposure to estrogen could (i) inhibit STIM1 
oligomerization, (ii) inhibit the STIM1-Orai1 interaction, or (iii) block Orai1 from 
conducting Ca2+.  To test this hypothesis, we performed several microscopy based 
assays to measure various aspects of STIM1 function.    
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Figure 1.1. Regulation of ASL.  Left, In normal airways, CFTR and CaCC are present 
to regulate ASL hydration.  CFTR is the main Cl- channel and when active indirectly 
inhibits ENaC.  Coordinated beating of cilia propels mucus up and out of the airways to 
remove trapped pathogens.  Right, In CF, CFTR is absent, but CaCC is still present and 
can partially regulate ASL hydration.  However, CaCC is insufficient to maintain normal 
hydration due to hyperabsorption of Na+ through ENaC.  This eventually causes the ASL 
to dehydrate, resulting in the collapse of cilia and mucus stasis. 
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Figure 1.2. The Store-Operated Ca2+ Entry Pathway.  A, Under resting conditions, 
cytoplasmic Ca2+ levels are low and ER Ca2+ stores are full.  Thus, STIM1 is inactive and 
extracellular Ca2+ is not transported into the cell through Orai1.  B, When a cell is 
stimulated with a GPCR, such as P2Y2, the SOCE pathway is initiated.  The active G 
protein recruits PLC to convert PIP2 into IP3, which activates the IP3-R to release ER 
Ca2+.  STIM1 senses ER Ca2+ depletion through its EF-hand and undergoes a 
conformational change and oligomerizes.  STIM1 oligomers translocate to the ER-
plasma membrane junction where they interact with Orai1 to induce Ca2+ influx.  
Elevated levels of cytoplasmic Ca2+ result in the activation of CaCC. 
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Figure 1.3. Functional domains of STIM1.  STIM1 is 685 amino acids in length and 
contains several known domains.  The N-terminus contains the EF hand (aa 67-96) to 
sense ER Ca2+ levels.  The SAM domain (aa 132-200) is important for oligomerization 
after ER Ca2+.  Following a single transmembrane (TM) domain (aa 215-234) is the ERM 
domain (aa 251-535), which contains two coiled-coils (aa 251-389).  The second coiled-
coil is encompassed by the SOAR domain (aa 344-442).  SOAR mediates interaction of 
STIM1 with Orai1 to induce Ca2+ influx.  The C-terminus of STIM1 contains the S/P rich 
region (aa 600-629) that contains several known serine phosphorylation sites and the K 
rich region (aa 672-685) that stabilizes localization of STIM1 near the plasma 
membrane.  Adapted from [168]. 
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Figure 1.4. Predicted Topology of Ano1.  Ano1 is predicted to contain 8 
transmembrane domains with intracellular N- and C-termini.  There is a predicted re-
entrant loop between transmembrane regions 5 and 6.  Ano1 contains four splice variant 
segments.  Segments a and b reside in the large N-terminus while segments c and d are 
in the first cytoplasmic loop. 
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Figure 1.5. Potential Effect of E2 on ASL Hydration.  Top, In normal males, CFTR, 
CaCC, and ENaC are present to maintain normal ASL hydration.  In males with CF, 
CFTR is lost, however CaCC is still present, which is activated in response to an 
elevation in intracellular Ca2+.  After ER Ca2+ depletion STIM1 activates Orai1 to induce 
Ca2+ influx, which activates CaCC.  Consequently, CaCC may be able to partially 
regulate ASL hydration.  Bottom, In normal females with elevated E2 levels, CaCC is 
inhibited as a result of inhibiting Ca2+ influx.  E2 may inhibit STIM1 or Orai1 to block 
extracellular Ca2+ influx.  However, due to the presence of CFTR, ASL hydration is 
maintained normally.  In CF females with elevated E2 levels, CaCC is inhibited and Cl- 
secretion is completely lost.  This may further decrease ASL hydration, leaving CF 
females prone to infection and an acute exacerbation.   
__________________________ 
This Research was originally published in the Journal of Biological Chemistry.  John T. 
Sheridan1, Erin N. Worthington1, Kuai Yu, Sherif E. Gabriel, H. Criss Hartzell and Robert 
Tarran. Characterization of the oligomeric structure of the Ca(2+)-activated Cl- channel 
Ano1/TMEM16A. J Biol Chem. 2011 Jan 14;286(2):1381-8. © the American Society for 
Biochemistry and Molecular Biology. 
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Chapter II 
Characterization of the Oligomeric Structure of the Ca(2+)-Activated Cl- 
Channel Ano1/TMEM16A 
 
 
2.1 Overview 
Members of the Anoctamin (Ano)/TMEM16A family have recently been identified 
as essential subunits of the Ca2+-activated chloride channel (CaCC). For example, Ano1 
is highly expressed in multiple tissues, including airway epithelia, where it acts as an 
apical conduit for transepithelial Cl− secretion and helps regulate lung liquid homeostasis 
and mucus clearance. However, little is known about the quaternary structure of this 
protein in the plasma membrane. Thus, utilizing mCherry- and eGFP-tagged Ano1 
constructs, we conducted biochemical and Förster resonance energy transfer (FRET)-
based experiments to determine the quaternary structure of Ano1. FRET and co-
immunoprecipitation studies revealed that tagged Ano1 subunits directly associated 
before they reached the plasma membrane. This association was not altered by 
changes in cytosolic Ca2+, suggesting that this is a fixed interaction. To determine the 
oligomeric structure of Ano1, we performed chemical cross-linking, non-denaturing 
PAGE, and electromobility shift assays, which revealed that Ano1 forms dimers. These 
experiments are the first to probe the quaternary structure of Ano1. Understanding the 
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oligomeric nature of Ano1 is an important step in the development of therapeutic drugs 
that could be useful in the treatment of cystic fibrosis. 
 
2.2 Introduction 
Ca2+-activated Cl- channels (CaCCs) play essential roles in many physiological 
processes including epithelial secretion [94], olfactory transduction [110, 169, 170], 
photoreceptor adaptation [171], regulation of smooth muscle contraction [172], neuronal 
and cardiac action potential waveform and firing frequency [173], and nociception [174].  
Because of their physiological significance, CaCCs have attracted attention for decades 
[175, 176]. However, their molecular composition has remained elusive until recently 
when three laboratories independently identified members of the Anoctamin 1 (Ano1) 
family, also known as the Transmembrane Protein 16 (TMEM16) family, as essential 
subunits of CaCCs [105-107].  Ano1/TMEM16A is highly expressed in secretory 
epithelial tissues including ductal glands, superficial epithelia of the airway, and oviduct, 
where it has been implicated in calcium-dependent chloride secretion [105, 107, 177-
179].  Ano1 has attracted particular attention in the airways, because it has been 
suggested that activating this channel might be therapeutically beneficial for treating 
cystic fibrosis (CF) patients [178]. The cystic fibrosis conductance regulator (CFTR) 
chloride channel is absent or defective in CF epithelia, leaving Ano1 as a potential 
alternative pathway to effect transepithelial Cl- secretion. 
  The anoctamin family consists of 10 members, all of which are predicted to have 
8 transmembrane domains with cytosolic N- and C-termini.  Ano1 is regulated by both 
intracellular Ca2+ and by voltage, in a similar fashion to native CaCCs [21], but the 
mechanisms are not well defined [180]. The homology between family members 
suggests that other Anos may also function as CaCCs [181] and Ano2 has also been 
shown to mediate the Ca2+-activated Cl- current in olfactory epithelium and 
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photoreceptor synapses [110, 171, 182]. With the possible exception of Ano8 and 
Ano10, anoctamins are also predicted to have a re-entrant loop between 
transmembrane domains 5 and 6 that may contribute to Cl- selectivity [183, 184].  
A common property of ion channels is their oligomeric nature, which may be 
homo- or hetero-oligomeric [185].  For example, activation of the MthK/Ca2+-activated K+ 
channel from Methanobacterium thermoautrophicum, involves oligomerization of 4 
subunits [186] and it has been suggested that the mammalian Maxi-K K+ channel is 
activated by a similar mechanism [187].  Activation of CFTR Cl- channels involves 
dimerization of nucleotide binding domains [188], although whether CFTR enters the 
plasma membrane as a monomer or a dimer remains controversial [189, 190].  A first 
step in understanding how Ano1 is gated and regulated requires knowing whether the 
channel exists as a monomer or an oligomer and, if it oligomerizes, the number of 
interacting subunits.  Since little is known about how Ano1 forms a Cl- conducting 
channel in the apical membrane, we have used biochemical techniques and Förster 
resonance energy transfer (FRET)-based approaches to investigate its subunit 
assembly.   
 
2.3 Materials and Methods 
Cell Culture.  Human excess donor lungs and excised recipient lungs were 
obtained at the time of lung transplantation from portions of main stem or lumbar bronchi 
and cells were harvested by enzymatic digestion as previously described under a 
protocol approved by the UNC School of Medicine IRB.  Human bronchial epithelia cells 
were transfected with Ano1 constructs in suspension using the Amaxa system (Lonza) 
as per the manufacturer’s instructions and were cultured overnight on 30 mm glass 
coverslips before imaging.  HEK293 cells were maintained in minimum essential medium 
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supplemented with 10% fetal bovine serum and 1X penicillin/streptomycin solution. 
HEK293 cells were typically used 2-3 days after seeding on 30 mm glass coverslips. 
Cultures that were ~75% confluent were transfected for 4-6 hours using Lipofectamine 
2000 (Invitrogen) as per the manufacturer’s instructions and allowed to incubate in 5% 
CO2 at 37°C overnight before use. 
Ano1 Constructs and RT-PCR.  Mouse Ano1 C-terminally fused with enhanced 
GFP (Ano1-eGFP) was kindly provided by Dr. Uhtaek Oh (Seoul National University, 
Korea; variant containing a and c alternative splice sequences, UniProtKB accession 
number Q8BHY3.2).  Ano1-eGFP is in the pEGFP vector (Clontech).  The Ano1-
mCherry construct was made by replacing eGFP with monomeric Cherry (mCherry, 
Clontech).  In both constructs, the fluorescent tag was separated from the C terminus of 
Ano1 by a 17 amino acid linker RILQSTVPRARDPPVAT to ensure that the fluorescent 
protein did not affect Ano1 function as previously described [191].  HA-tagged P2Y2 
receptor construct was donated by Kendall Harden (Department of Pharmacology, 
UNC, Chapel Hill, North Carolina, USA)[192]. Endogenous expression of all Ano family 
members (Ano1-10) was determined by RT-PCR using primers for Ano1 as listed in 
Table 1. 
Patch Clamping.  Whole-cell patch clamp recording was performed with an 
Axopatch 200B amplifier as previously reported [193]. The voltage clamp protocol 
consisted of 750 ms duration steps from a 0 mV holding potential to various potentials 
between -100 mV to +100 mV in 20 mV increments. Fluorescent cells were chosen for 
recording. The pipette solution contained (in mM): 146 CsCl, 2 MgCl2, 5 EGTA, 0 or 
5.0143 CaCl2 to make a free [Ca
2+] of 0 or 1 µM, 10 sucrose, and 8 HEPES pH 7.3 
adjusted with NMDG. The standard external solution contained (in mM): 140 NaCl, 4 
KCl, 2 CaCl2, 1 MgCl2, 10 glucose, 10 HEPES, pH 7.3.  
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Acceptor-photobleaching FRET.  FRET was performed using a Leica SP5 
confocal microscope with a 63X glycerol immersion objective. The donor (eGFP) was 
excited at 488 nm and emission collected from 495 nm to 549 nm and the acceptor 
(mCherry) was excited at 561 nm and emission collected from 580 nm to 654 nm. FRET 
was measured by the acceptor photobleaching method and analyzed using ImageJ (NIH 
Freeware).  The FRET efficiency (%E) was calculated as:  ((donorpostbleach-
donorprebleach)/donorpostbleach)*100. 
Measurements of Ca2+i.  All cultures were loaded with Fura-2-AM (5 µM at 37ºC 
for 40 min) and imaged with a 40 x 1.2 NA H2O objective on a Nikon Ti-S microscope. 
Ca2+i measurements were obtained using an Orca camera (Hamamatsu) and Fura-2 
fluorescence was acquired alternately at 340 and 380 nm (emission >450 nm) using 
Ludl filter wheels with Compix sPCI software. At each excitation wavelength (340 or 380 
nm), background light levels were measured by exposing cells to digitonin (15 μM) and 
MnCl2 (10 mM) and subtracting the emission from the corresponding signal measured in 
Fura-2–loaded cells before taking the ratio (340/380) [15].  
Imaging of the actin cytoskeleton.  For labeling of actin, HEK293 cells grown on 
glass coverslips. Cells were incubated with 1 µM cytochalasin D or vehicle (0.1% 
DMSO) for 30 min and were then fixed in 4% PFA for 10 min at room temperature. After 
washing 3 x in PBS, cells were permeabilized by a 10 min exposure to 1% Triton X. After 
a 3 x wash, cells were incubated with Alexa488 phalloidin (Invitrogen) for 30 min, 
followed by deep red HCS cell mask (Invitrogen) for 30 min as per the manufacturer’s 
instructions.  Fixed cells were then imaged immediately using the Leica SP5 confocal 
microscope.  
Co-immunoprecipitation and western-blotting.  Co-immunoprecipitation was 
performed in HEK293 cells transfected with Ano1-mCherry and Ano1-eGFP, adenosine-
2B receptor-eGFP (A2BR-eGFP), or eGFP.  Cells were lysed in 600 µl NP-40 lysis 
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buffer (0.09% NP-40, 50 mM Tris-HCl, pH 7.4, 10 mM NaMoO4, 150 mM NaCl) 
supplemented with 1X complete EDTA-free protease inhibitors (Roche).  Lysates were 
then centrifuged at 16,000 x g for 10 min at 4°C and the supernatants were collected.  
Protein concentrations were determined by the BCA protein assay kit (Pierce) and equal 
amounts of protein (800 µg) were diluted to 1.6 µg µl-1 with NP-40 lysis buffer in spin 
columns (Pierce) and mixed with anti-mCherry monoclonal antibody (Clontech) and 
rotated at 4°C for 2 hours.  Protein A/G agarose beads (30 µl, Pierce) were added to 
lysate and rotated at 4°C for 4 hours.  Beads were washed three times with NP-40 lysis 
buffer by centrifugation at 1500 x g for 2 minutes at 4°C and protein was eluted by 
boiling in 2X concentrated sample buffer (1% SDS, 5% glycerol, 25 mM Tris-HCl, pH 
6.8, 0.01% bromophenol blue, 0.5% 2-mercaptoethanol).  Protein was resolved on a 3-
8% gradient NuPAGE Tris-acetate gels (Invitrogen) and transferred to nitrocellulose 
using iBlot (Invitrogen).  Immunoblots were incubated overnight at 4°C with the either 
anti-mCherry monoclonal antibody (Clontech, 1:1000) or rabbit polyclonal anti-eGFP 
antibody (Abcam, 1:1000) in 2% fish gelatin blocking buffer.  Proteins were detected 
using SuperSignal West Pico Chemiluminescent Substrate kit (Pierce) or using Goat 
anit-Rabbit IRDye 800CW antibody (1:10,000) in 2% fish gelatin blocking buffer and 
analyzed with the Odyssey IR imaging system (LI-COR Biosciences). 
Chemical cross-linking.  Chemical cross-linking was performed as described [78].  
Ano1-eGFP transfected HEK293 cells were lysed in cross-linking buffer (PBS pH 8).  
Protein was incubated with varying concentrations of the cross-linker 1,5-difluoro-2,4-
dinotrobenzene (DFDNB, Pierce) (water-insoluble, membrane permeable, spacer arm 
length 3 Å) at 37°C for 10 min.  The cross-linking reaction was stopped by the addition of 
20 mM Tris, pH 7.5 and incubated at room temperature for 20 min.  Samples were mixed 
with 4X NuPAGE LDS sample buffer containing 50 mM dithiothreitol (DTT) and 
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incubated at 70°C for 10 min.  Protein was resolved on a 3-8% NuPAGE Tris-acetate 
gels and analyzed by western-blotting. 
NativePAGE.  Cells were sonicated in 600 l NativePAGE 4X sample buffer 
containing 2% n-dodecyl β-D-maltoside (DDM) (Invitrogen).  Lysate was centrifuged at 
16,000 x g for 10 min at 4°C.  Supernatant was collected and 10 g of protein was 
treated with varying concentrations of SDS and treated with 0.5% G-250 (Invitrogen).  
Protein was resolved on NativePAGE Novex 4-16% Bis-Tris gel and detected by 
western-blotting. 
Electromobility Shift Assay.  Whole cell HEK293 lysate expressing Ano1-eGFP 
and Ano1-mCherry was obtained for electromobility shift assay (EMSA) analysis.  Whole 
cell lysate containing 7.5 µg of protein was prebound with anti-mCherry at 4 °C for 1 
hour.  Prebound lysate was then subjected to non-denaturing PAGE.  Protein shift was 
resolved by western-blotting with anti-GFP. 
Statistical Methods.  All data are presented as the mean ± SE for n number of 
cells. Each transfection was repeated on at least three separate days. Differences 
between means were tested for statistical significance using paired or unpaired t tests or 
their non-parametric equivalent as appropriate to the experiment. From such 
comparisons, differences yielding p ≤ 0.05 were judged to be significant. 
 
2.4 Results 
Ano expression and verification of Ano1 construct function.  We have previously 
shown that HEK293 cells do not endogenously express a Ca2+ activated Cl- current 
[194].  However, to determine that these cells did not endogenously express Ano1, we 
performed RT-PCR (Fig. 2.1A). Consistent with the lack of an endogenous CaCC (see 
also Fig. 2.1E), these cells did not express Ano1. However, Ano 2, 4, 5, 6, 8 and 10 
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were endogenously expressed, suggesting that these additional Ano family members 
are not capable of forming a CaCC in these cells.   
To probe the quaternary structure of Ano1, we fused eGFP and mCherry to the 
C-termini of Ano1. We then verified that these FRET constructs could still be activated 
by intracellular Ca2+ to conduct Cl-. With nominally zero intracellular Ca2+, both tagged 
constructs and the untagged wild type Ano1 failed to display significant currents (< 0.05 
nA; Fig 2.1E).  However, in the presence of 1 μM free intracellular Ca2+, whole cell 
currents were typically >5nA for all Ano1s (Fig. 2.1B-E).  Importantly, the currents from 
both constructs exhibited outward rectification and time dependence that was typical of 
CaCC currents at this Ca2+ concentration and was identical to untagged Ano1 (Fig. 2.1B-
E) [104]. These results demonstrate that attaching eGFP or mCherry had no obvious 
effect on Ano1 function.   
Ano1-eGFP and Ano1-mCherry undergo FRET in the plasma membrane of 
HEK293 cells and airway epithelia. We first used FRET to search for Ano1-Ano1 
interactions since this method allows for live-cell quantification. As a positive FRET 
control, we directly linked eGFP to mCherry by five glycines (in the absence of Ano1) 
and measured the % FRET with this construct in HEK293 cells using the acceptor 
photobleaching approach [195].  Typical acceptor photobleaching of this FRET pair is 
shown in Fig. 2.2A, B.  We were able to measure 48 ±1% FRET with this construct (Fig. 
2.2C, D), which is close to the maximal FRET that is measurable between eGFP and 
mCherry (50%) [196], suggesting that we can accurately measure FRET with our 
system.  In contrast, unlinked eGFP and mCherry did not undergo FRET when co-
expressed in HEK cells (Fig. 2.2D).  
24 h after transfection in HEK293 cells, Ano1 was predominantly expressed in 
the plasma membrane (Fig. 2.3A) and after acceptor photobleaching (Fig. 2.3B) we 
detected significant FRET of 8% (Fig. 2.3C, D), suggesting that Ano1 subunits were 
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close enough to interact. To determine whether Ano1 channels associate before they 
reach the plasma membrane, we measured Ano1 FRET ~15 h post transfection when 
the majority of Ano1 is located intracellularly.  Intracellular Ano1-eGFP - Ano1-mCherry 
FRET was also ~8% (Fig. 2.3D), suggesting that Ano1 oligomers assemble before 
reaching the plasma membrane.  
We failed to detect any FRET between eGFP alone and Ano1-mCherry, 
suggesting that the Ano1 FRET was due to the specific assembly of Ano1 subunits. To 
test for the possibility that the plasma membrane of a HEK293 may become crowded 
following transient transfections, forcing an intimacy that would not normally occur, we 
co-expressed Ano1-mCherry and eGFP-tagged A2B adenosine receptor (A2BR-eGFP), 
a G-protein coupled receptor that resides in the plasma membrane but has not 
previously been shown to interact with Ano1.  In this case, there was a small, but 
significant, amount of FRET (2%), which was significantly less than the 8% FRET seen 
between Ano1 subunits (Fig. 2.3D).  Co-expressed Ano1-mCherry and eGFP-tagged 
CFTR also returned moderate FRET (~3.5%) that was also significantly less than the 8% 
FRET seen between Ano1 subunits (Fig. 2.3D).  Together, these low levels of FRET are 
perhaps indicative of the restricted 2-dimensional diffusion that limits distances between 
two proteins that do not physically interact in the plasma membrane.  
To demonstrate that Ano1-Ano1 FRET was not influenced by the expression 
system used, we co-expressed the Ano1 constructs in single primary human bronchial 
epithelial cells. We again observed close to 8% FRET in these cells, suggesting that the 
Ano1 interaction is an intrinsic property of Ano1, rather than an intimacy forced by the 
HEK293 expression system (Fig. 2.3D).  
Ano1 FRET is due to a protein-protein interaction.  To confirm that FRET between 
Ano1-eGFP and Ano1-mCherry was due to a physical interaction, we co-
immunoprecipitated Ano1-mCherry and Ano1-eGFP using antibodies specifically raised 
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against eGFP and mCherry (Fig. 2.4A). As a negative control, we immunoprecipitated 
Ano1-mCherry from HEK293 cells co-expressing A2BR-eGFP or eGFP and probed with 
an eGFP antibody (Fig. 2.4A).  No bands were detected after blotting for eGFP in control 
lanes, indicating that these proteins do not interact with Ano1.  Western blotting 
confirmed that both antibodies are specific for eGFP/mCherry respectively and neither 
detected the other fluorescent protein (Fig. 2.4B). 
Ano1 FRET is not altered by changes in intracellular Ca2+ or actin cytoskeleton 
disruption.  We next tested whether changes in intracellular Ca2+ could alter Ano1 FRET.  
Intracellular Ca2+ was raised with 2 µM thapsigargin [21], 100 µM UTP [15], or 10 µM 
ionomycin [197].  Cells treated with UTP were also transfected with an HA-tagged P2Y2 
receptor construct (P2Y2R-HA) to ensure a consistent UTP response. HEK293 cells 
displayed a robust increase in the fura-2 emission ratio after all three treatments (Fig. 
2.5A, C, E).  However, these maneuvers failed to affect Ano1 FRET (Fig. 2.5B, D, F), 
suggesting that Ano1-Ano1 interactions are not influenced by changes in intracellular 
Ca2+. 
Epithelial ion channels have been shown to be linked to the cytoskeletal 
infrastructure by postsynaptic density 95 discs large zonula occludens-1 (PDZ) binding 
motifs and these interactions can be ablated by disrupting F-actin polymerization with 
cytochalasin D [198].  However, a 30 min treatment with 1 µM cytochalasin D, which 
extensively disassembled the cytoskeleton, had no effect on Ano1 localization to the 
plasma membrane or Ano1-Ano1 FRET, suggesting that oligomerization of Ano1 is not 
contingent on binding to the actin cytoskeleton (Fig. 2.6). 
Biochemical evidence that Ano1 is a dimer.  In order to investigate the 
stoichiometry of Ano1 oligomers, we performed chemical cross-linking experiments on 
cell lysates obtained from HEK293 cells expressing Ano1-eGFP (Fig. 2.7A).  Under 
control (i.e. DMSO) conditions, Ano1-eGFP was seen predominantly as a ~130 kDa 
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monomer.  However, after treating whole cell lysate with the cross-linker 1,5-difluoro-2,4-
dinotrobenzene (DFDNB), an additional band was observed which corresponded to an 
Ano1-eGFP dimer (~260 kDa). Two faint higher-order bands were also visible.  
However, the molecular weight of these bands was harder to ascertain and they may 
represent non-specific crosslinking of Ano1 to other membrane proteins. 
We next performed non-denaturing PAGE on lysate obtained from HEK293 cells to 
validate the cross-linking experiments (Fig. 2.7B).  Cells were lysed by 2% DDM and 
sonication in the absence of SDS.  The majority of Ano1 appeared as a dimer with no 
presence of higher order bands.  Inclusion of SDS induced the emergence of a ~117 
kDa band indicating that Ano1 had been fully denatured and that we were observing the 
monomeric protein.  This band was slightly smaller than the predicted size of Ano1-
eGFP (~130 kDa), but is consistent with an apparent reduction in protein size seen 
under non-reducing conditions [199].  To ensure that we were observing Ano1-eGFP 
dimers and not Ano1-eGFP in association with an unidentified endogenous protein, we 
performed an electromobility shift assay (EMSA) by exposing lysate from HEK293 cells 
expressing Ano1-eGFP and Ano1-mCherry to an mCherry antibody before non-
denaturing PAGE (Fig. 2.7C).  We then blotted for eGFP to test whether Ano1-eGFP 
was shifted higher molecular weight by antibody pre-binding.  A portion of Ano1-eGFP 
remained at 230 kDa, which likely represented a homodimer population of Ano1-eGFP 
alone.  Importantly, we observed a distinct shift of Ano1-eGFP to a higher molecular 
weight, which corresponded to a complex containing Ano1-eGFP, Ano1-mCherry, and 
the mCherry antibody.  
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2.5 Discussion 
We examined the stoichiometry of Ano1 using biophysical and biochemical 
approaches.  We used HEK293 cells since they do not endogenously express Ano1 
(Fig. 2.1A) and do not have a spontaneous CaCC, even with 1 µM Ca2+ in the patch 
pipette (Fig. 2.1E). For our studies, we C-terminally labeled murine Ano1 with either 
eGFP or mCherry. To ensure that these fluorescent proteins did not interfere with Ano1 
function, we included a 17 amino acid linker between Ano1 and eGFP or mCherry.  
Importantly, these fluorescent proteins had no effect on Ano1-mediated Cl- currents, 
suggesting that their use in this endeavor was valid (Fig. 2.1).   
We chose eGFP/mCherry over the more commonly used CFP/YFP FRET pair 
since CFP photobleaches easily, which reduces its ability to accept photons during 
FRET, while eGFP is significantly more photostable [200]. This approach was confirmed 
using a FRET positive construct where the acceptor was linked to the donor by 5 
glycines (Fig. 2.2). The theoretical maximum FRET that can occur between two 
fluorescent proteins (including CFP, eGFP, mCherry and YFP) is 50%, which is limited 
by the size of the fluorescent proteins themselves [196].  Using CFP linked to YFP, we 
measured 38% ± 3 FRET (n=6).  In contrast, we measured 48% ± 1 FRET (n=14) with 
eGFP linked to mCherry, confirming previous reports that the latter FRET pair is 
significantly more suited for confocal microscopy (Fig. 2.2) [200].  
Using acceptor-photobleaching FRET, we found a remarkably constant 8% 
FRET between Ano1-eGFP - Ano1-mCherry (Fig. 2.3), which suggested that Ano1 can 
oligomerize.  Co-immunoprecipitation experiments revealed that Ano1-eGFP and Ano1-
mCherry are associated.  In contrast, Ano1-mCherry did not co-immunoprecipitate with 
A2BR-eGFP, suggesting that the observed 2% FRET between these proteins was due 
to moderate proximity in the plasma membrane, and not a direct physical interaction.  
Many other apical membrane ion channels are known to oligomerize.  For example 
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ENaC is a hetero-multimer that returns between 5-15% FRET between different ENaC 
subunits [201].  ENaC is also known to interact with CFTR [202] and FRET was 7% 
between CFTR and all three ENaC subunits [202]. A study by Kerschensteiner et al. 
used acceptor-photobleaching FRET to determine the stoichiometry of voltage-gated K+ 
(Kv) channels that are known to be heteromeric oligomers [203].  They obtained ~25% 
FRET efficiency when Kv2.1-CFP and Kv9.3-YFP were expressed compared to a ~10% 
FRET efficiency when Kv2.1-YFP and Kv9.3-CFP were expressed.  Thus, the 8% FRET 
that we record between Ano1 subunits is comparable to both FRET seen both between 
ion channel subunits and between distinct ion channels. Perhaps, surprisingly, while 
CFTR has previously been shown to negatively regulate CaCC [204, 205], we detected 
only minimal FRET between CFTR and Ano1 (Fig. 2.3), suggesting that regulation of 
Ano1 by CFTR is not due to a direct interaction.  Since we found Ano1-Ano1 FRET to be 
8% when measured intracellularly (Fig. 2.3), it is likely that Ano1 subunits come together 
en route to the plasma membrane.  It should be noted that we did not differentiate 
between intracellular compartments during our analysis and subunits may oligomerize 
as early as the ER or as late as endosomes. 
CFTR indirectly binds to the actin cytoskeleton via its C-terminal PDZ-binding 
motif and disruption of F-actin polymerization with cytochalasin D affects CFTR activity 
[206, 207].  Performing a computational search with the Eukaryotic Linear Motif resource 
(www.elm.eu.org), we found that murine Ano1 also has a predicted C-terminal PDZ-
binding motif (GDAL) which may serve to link Ano1 to the actin cytoskeleton through 
intermediary scaffolding proteins.  However, the ability of Ano1 to undergo FRET was 
not affected by cytochalasin D exposure, suggesting that Ano1 subunit interactions are 
not cytoskeleton-dependent (Fig. 2.6).  However, the effect of cytochalasin D on 
trafficking remains to be determined.  We also found Ano1 FRET to be insensitive to 
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intracellular Ca2+ levels (Fig. 2.5), suggesting that Ano1 oligomerization is fixed and 
independent of Ano1’s gating ability, which is Ca2+-dependent [105-107]. 
Chemical-cross linking and non-denaturing PAGE assays indicated that Ano1 is 
a dimer (Fig. 2.7).  A distinct dimer band was observed following chemical-cross linking 
(Fig. 2.7A), which was not observed under control conditions.  Additional higher order 
complexes were also observed after cross linking.  However, these may be proteins that 
are non-specifically cross linked to Ano1-eGFP.  Following non-denaturing PAGE a 
strong dimer band was also observed (Fig. 2.7B).  This dimerization was only disrupted 
with 3% SDS (Fig. 2.7B).  Higher order oligomers were not detected by non-denaturing 
PAGE, suggesting those observed following cross linking are not true oligomers.  We 
next performed EMSA analysis to determine if the dimer band consists of two Ano1 
proteins or Ano1 with an unidentified endogenous protein (Fig. 2.7C).  This approach 
revealed a shift of Ano1-eGFP to a higher molecular weight when prebound with an anti-
mCherry antibody, confirming that Ano1-eGFP was present as a dimer with Ano1-
mCherry and not with any other protein.  Since only Ano1 is present under non-
denaturing conditions, it is likely that the co-immunoprecipitation is indicative of a direct 
interaction between Ano1 subunits (Fig. 2.4).  A portion of Ano1-eGFP did not shift to a 
higher molecular weight.  This is likely due to the fact that HEK293 cells transfected with 
Ano1-eGFP and Ano1-mCherry should yield three distinct populations of Ano1 dimers, 
consisting of Ano1-eGFP/Ano1-eGFP, Ano1-eGFP/Ano1-mCherry, and Ano1-
mCherry/Ano1-mCherry.   
While Ano1 has been identified as an essential subunit of CaCC [105-107], 
transiently expressed Ano1 could form a heteromultimer with other anoctamin family 
members since many of these proteins are ubiquitously expressed (Fig. 2.1A).  Our data 
suggest that native Ano1 specifically forms a homodimer, and that Ano1-eGFP and 
Ano1-mCherry are functional proteins that can dimerize.  Determining the oligomeric 
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structure of CaCC is an important step towards a better understanding of how this 
recently identified channel functions.  Further work is needed to determine how Ano1 
subunits come together, whether other proteins facilitate the process, and how this 
affects activation of CaCC and conductance of Cl-. 
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Table 2.1 
Primers used in RT-PCR to detect endogenous anoctamin expression in HEK293 cells 
Gene Sense Antisense 
Ano1 GCGTCCACATCATCAACATC ATCCTCGTGGTAGTCCATCG 
Ano2 TGCCTACCACTACCGGAAAC ACTTCTTTGCAATGCTGCCT 
Ano3 AAACCTGAACCACATCAGCC TCTTCCCAAAAAGAAAGCGA 
Ano4 CATGGGAAGTCCTTGGAAGA GCCATTGGTAAGCAAACGAT 
Ano5 ACACTTCACCAGAATTGGGC GAAGCTGCTGCTGTTCCTCT 
Ano6 CAGTTTGGGTTCGTCACCTT AGTACGGGTTTCCCTTGCTT 
Ano7 CTACTCCTGCCGGTTCAGAG GTTCCTGCGTGGGTATGTCT 
Ano8 ACTTCGCTCTGCTCCTCAAG CTTCATGACGTTGTTGGGTG 
Ano9 TGGAGATCAGCACCTGTGAG CGAAGTTCACGATTCGGATT 
Ano10 GAGGTGCCCAGTTGTTGTTT CCGAGTGTACCAGGTGTCCT 
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Figure 2.1. Ca2+-activated Cl- Currents induced by fluorescent protein-tagged 
mouse Ano1 constructs are identical to wild type Ano1. HEK293 cells were 
transiently transfected and subjected 1 day later to whole cell patch clamp recording.  A, 
total RNA was collected from untransfected HEK293 cells and RT-PCR was performed 
to determine which Ano proteins are endogenously expressed.  Ano5, 6, and 10 were 
strongly expressed while Ano2 and 4 were mildly expressed.  Ano1, 3, 7, 8, and 9 were 
not detectable.  B, Wild type mouse Ano1 (variant containing a and c alternative splice 
sequences, accession Q8BHY3.2). C, Ano1 tagged with eGFP on the C-terminus.  D, 
Ano1 tagged with mCherry on the C-terminus. E, Steady-state current-voltage 
relationships (red square, wild type; black square, mCherry-tagged Ano1; blue square, 
eGFP-tagged Ano1; circle, untransfected).  All n=10. N.B., in some cases, error bars 
were obscured by the symbols. * denotes p <0.05 different to basal currents.  These 
experiments were conducted by Dr. Kuai Yu and Dr. Criss Hartzell. 
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Figure 2.2. eGFP linked to mCherry with 5 glycines (eGFP-5G-mCherry) undergoes 
near-maximal FRET.  A, Typical confocal micrographs of eGFP-5G-mCherry (green, 
donor; red, acceptor) before and after photobleaching of the acceptor fluorophore.  B, 
Graph showing typical acceptor photobleaching over 10 s.  C, Resultant FRET image 
from A.  D, Mean FRET efficiency (%E) of unlinked eGFP and mCherry cotransfected in 
the same cells (n=10) and from eGFP-5G-mCherry (n=14).  * denotes p <0.05 different 
between linked and unlinked eGFP and mCherry.  Scale bar represents 25 µm. 
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Figure 2.3. Ano1-eGFP and Ano1-mCherry undergo specific FRET in the plasma 
membrane.  A, Typical confocal micrographs of Ano1-eGFP (green, donor) and Ano1-
mCherry (red, acceptor) before and after photobleaching of Ano1-mCherry. B, Graph 
showing typical acceptor photobleaching over 10 s. C, Resultant FRET image calculated 
from A.  D, Mean FRET efficiency (%E).  Open bars, plasma membrane FRET in 
HEK293 cells (n=56) and human bronchial epithelial cells (n=13). Closed bar, 
intracellular FRET in HEK293 cells (n=36). Gray bars, FRET between Ano1-mCherry 
and the denoted acceptor molecule.  eGFP – Ano1-mCherry (n=19); A2BR-eGFP – 
Ano1-mCherry (n=19); CFTR-eGFP – Ano1-mCherry (n=22).  * denotes FRET that is p 
<0.05 different from 0.  † denotes FRET that is p <0.05 different to plasma membrane 
Ano1 FRET in HEK293 cells.  Scale bar represents 25 µm. 
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Figure 2.4. Ano1-eGFP and Ano1-mCherry co-immunoprecipitate.  A, HEK293 cells 
were transfected with lipofectamine alone, or with Ano1-mCherry and either Ano1-eGFP, 
A2B-R-eGFP, eGFP.  Input represents 5% of total protein used in co-
immunoprecipitation.  B, Western blot indicating specificity of eGFP and mCherry 
antibodies.  HEK293 cells were transfected with either Ano1-eGFP or Ano1-mCherry.  
The eGFP antibody only detected Ano1-eGFP (left) while mCherry antibody only 
detected Ano1-mCherry (right).  Blot is representative of three separate experiments. 
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Figure 2.5. Ano1-eGFP and Ano1-mCherry FRET is not affected by changes in 
intracellular Ca2+.  A, typical fura-2 emission ratio observed following exposure to 2 µM 
thapsigargin (n=10).  B, mean FRET (%E) from Ano1 in the plasma membrane of 
HEK293 cells after vehicle (open bars; n=25) and following 5 min exposure to 2 µM 
thapsigargin (closed bars; n=27).  C, typical fura-2 emission ratio observed following 
exposure to 1 µM ionomycin (n=10).  D, Mean FRET (%E) from Ano1 in the plasma 
membrane of HEK293 cells after vehicle (open bars; n=20) and following 5 min exposure 
to 1 µM ionomycin (closed bars; n=21).  E, typical fura-2 emission ratio observed 
following exposure to 10 µM UTP (n=10).  F, Mean FRET (%E) from Ano1 in the plasma 
membrane of HEK293 cells after vehicle (open bars; n=20) and following 5 min exposure 
to 10 µM UTP (closed bars; n=20). 
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Figure 2.6. Ano1-eGFP and Ano1-mCherry FRET is not dependent on an intact 
actin cytoskeleton.  Left, Confocal micrographs of Ano1-mCherry in HEK293 cells (red) 
before and after disruption of actin cytoskeleton (phalloidin/green) with 1 µM 
cytochalasin D for 30 min.  Right, mean %E in HEK293 cells after vehicle (open bars; 
n=36) and after 30 min cytochalasin D exposure (gray bars; n=49).  Scale bar represents 
25 µm. 
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Figure 2.7. Determination of Ano1 subunit stoichiometry by chemical cross-linking 
and non-denaturing gel electrophoresis.  A, Determination of possible oligomeric 
structures of Ano1-eGFPusing chemical cross-linking.  Cell lysates were treated with 
increasing concentrations of DFDNB (1,5-difluoro-2,4-dinotrobenzene, membrane 
permeable).  * Denotes possible higher order complexes or adducts.  B, Determination 
of oligomeric structure of Ano1-eGFP under non-denaturing (native) PAGE conditions.  
Cell lysates were incubated with 0-3% of SDS to denature protein complexes and 
probed.  Under non-denaturing conditions, Ano1 is found mainly as a dimer.  C, EMSA 
analysis from HEK293 cell lysate expressing Ano1-eGFP and Ano1-mCherry, showing a 
mobility shift elicited by anti-mCherry (arrow). 
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Chapter III 
17β-Estradiol Inhibits Phosphorylation of STIM1: Implication for Store-
Operated Calcium Entry and Chronic Lung Diseases 
   
 
3.1 Overview 
Sex plays a significant role in the development of lung diseases including 
asthma, cancer, chronic bronchitis and cystic fibrosis. In the latter, E2 may inhibit store-
operated Ca2+ entry (SOCE) to impinge upon airway secretions, leaving females at 
greater risk of contracting lung infections.  Stromal interaction molecule 1 (STIM1)-
mediated SOCE is essential for cell homeostasis and regulates numerous processes 
including cell proliferation, smooth muscle contraction and secretion. 17β-estradiol (E2) 
can signal non-genomically to modulate Ca2+ signaling, but little is known of the 
underlying mechanisms.  We found that E2 inhibited STIM1 translocation in airway 
epithelia, preventing SOCE.  This correlated with a decrease in STIM1-STIM1 FRET and 
STIM1 mobility in E2-exposed HEK293T cells co-expressing estrogen receptor α 
(ESR1).  We also examined the role of STIM1 phosphorylation in E2-mediated inhibition 
of STIM1 mobility.  Basal phosphorylation of STIM1 at serine 575 is required for SOCE.  
Exposure to E2 significantly decreased STIM1 phosphorylation.  Mutating serine 575 to 
an alanine blocked STIM1 phosphorylation, reduced basal STIM1 mobility and rendered 
STIM1 insensitive to E2.  These data indicate that E2 can signal non-genomically by 
inhibiting basal phosphorylation of STIM1, leading to a reduction in SOCE.
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3.2 Introduction 
Calcium is an important second messenger that controls cellular processes as 
varied as contraction, ion transport, regulation of transcription, growth and cell division 
[208].  Thus, precise regulation of cytoplasmic Ca2+ is required to maintain normal 
cellular homeostasis.  This is mainly achieved by sequestering Ca2+ to internal stores, 
such as the endoplasmic reticulum (ER) and mitochondria [209].  Following receptor-
mediated ER Ca2+ depletion, SOCE is used to further modulate cytoplasmic Ca2+ levels 
and to replenish depleted stores [30].  SOCE requires the ER Ca2+-sensing protein 
STIM1 [46, 54] and the Ca2+ release-activated Ca2+ channel subunit Orai1 [29, 31].  The 
N-terminal domain of STIM1 contains an EF-hand that protrudes into the lumen of the 
ER and senses changes in ER Ca2+ levels [30, 210].  Upon depletion of ER Ca2+, STIM1 
undergoes a conformational change and oligomerizes into puncta at the ER-plasma 
membrane junction, where it activates Orai1 to induce Ca2+ influx [30, 210].  In airway 
epithelia, one important consequence of agonist-dependent increases in Ca2+i is the 
subsequent activation of transepithelial Cl- secretion through the Ca2+-activated Cl- 
channel (CaCC).  In patients with CF, who the lack the CFTR Cl- channel, CaCC is still 
present and represents a “rescue” channel that may help maintain airway hydration in 
the absence of CFTR [14].   
Gender can greatly influence lung health [142].  For example, CF women have a 
poorer prognosis and are more likely to experience an acute exacerbation than CF men 
[135, 136].  Additionally, adult women are more likely to be diagnosed with early onset 
chronic obstructive pulmonary (COPD) disease [149], asthma [141], and 
adenocarcinoma of the lung [156].  We have previously shown that E2 inhibits agonist-
mediated Ca2+ signaling through ESR1 in a non-genomic fashion in airway epithelia, 
which ultimately prevents CaCC activation and leads to airway dehydration [167].  Here, 
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we tested the hypothesis that E2 inhibits key components of SOCE.  We found that 
STIM1 was specifically inhibited by E2/ESR1, leading to an inhibition of SOCE but not 
ER Ca2+ release.   
 
3.3 Materials and Methods 
Chemicals and Reagents.  17β-estradiol and all salts and buffers were obtained 
from Sigma-Aldrich.  Thapsigargin, Fura-2 AM and phalloidin were obtained from Life 
Sciences.  Antibodies were from Abcam (anti-GFP), Millipore (anti-mpm-2) and Sigma-
Aldrich (anti-STIM1).  cDNAs encoding YFP-tagged STIM1 and 570STOP-STIM1 
(truncation mutant) were kindly provided by T. Meyers (Stanford, CA, USA) and J. 
Putney (NIEHS, NC, USA) respectively.  mCherry-tagged STIM1 was created by 
replacing the YFP tag on STIM1 with mCherry.  CFP-ESR1 was kindly provided by R. 
Day (UVA, VA, USA) and subsequently tagged with mOrange.  Orai1-YFP and EB1-
GFP constructs were purchased from Addgene (Prod. #19756 and #39299).   
Cell Culture and transfections.  Human excess donor lungs and excised recipient 
lungs were obtained at the time of lung transplantation from portions of main stem or 
lumbar bronchi and cells were harvested by enzymatic digestion as previously described 
under a protocol approved by the UNC School of Medicine IRB [211].  Human bronchial 
epithelial cells (HBECs) were plated on either glass coverslips to perform siRNA 
knockdown experiments or on polyester membrane transwells (Corning) to induce 
polarization.  HBECs that were plated on transwells were grown in air-liquid interface for 
3 weeks prior to experiments.  HEK293T cells were maintained in MEM alpha media 
supplemented with 10% fetal bovine serum and 1 x penicillin/streptomycin solution. 
HEK293T cells were typically used 2-3 days after seeding. Cultures were transfected for 
4-6 hours using Lipofectamine 2000 (Life Sciences) as per the manufacturer’s 
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instructions.  After transfecting, cultures were washed and placed in phenol-free media 
and allowed to incubate in 5% CO2 at 37°C overnight.   
siRNA knockdown.  STIM1 and Orai1 were transiently knocked down in HBECs 
using the Amaxa Nucleofector system as per the manufacturer’s instructions with at 
least two different siRNA sequences obtained from Dharmacon.  STIM1 and Orai1 
knockdown were verified by qPCR and at the functional level by measuring changes in 
intracellular Ca2+ with Fura-2. 
Measurements of intracellular Ca2+.  Intracellular Ca2+ imaging experiments were 
performed as previously described [167].  Briefly, HEK293T and non-polarized HBEC 
cultures were loaded with 2 μM Fura-2 at 37°C for 15 min.  Polarized HBECs were 
loaded with 5 μM Fura-2 while in the presence on 1 mM probenecid at 37°C for 1 hour.  
Cultures were washed with a standard Ringer’s solution and then with Ca2+-free Ringer’s 
solution.  Cultures were then placed in Ca2+-free Ringer’s solution and images were 
collected with a 60 x 1.2 NA water objective on a Nikon Ti-S inverted microscope.  Fura-
2 fluorescence was acquired alternately at 340 and 380 nm (emission >450 nm) using 
LUDL filter wheels, obtained with an Orca CCD camera (Hammamatsu) and controlled 
with SimplePCI software.  Background light levels were measured and subtracted from 
the corresponding signal measured in Fura-2 loaded cells before calculating the ratio 
(340/380).  The background light levels in polarized HBECs were obtained by measuring 
the signals in non-Fura-2-loaded HBECs. 
Immunofluorescence.  Polarized HBECs were fixed bilaterally with 4% 
paraformaldehyde for 30 min at room temperature.  After washing 3 times with PBS, 
HBECs were permeabilized with 0.1% Triton-X for 10 min and incubated in blocking 
buffer (1% IgG free BSA, 1% Normal Goat Serum) at room temperature for 1 h.  HBECs 
were then incubated with an antibody against STIM1 in blocking buffer overnight at 4°C.  
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After washing with PBS, HBECs were incubated Alexa Fluor 568 goat anti-rabbit 
secondary antibody (Life Technologies) for 1 h at room temperature.  Actin was stained 
with Phalloidin-488 (Life Technologies) as per manufacturer’s instructions.  All antibodies 
and stains were applied bilaterally.  Images were analyzed using ImageJ (NIH 
Freeware). 
  STIM1 Puncta Quantification.  HEK293T cells expressing STIM1-mCherry and 
ESR1-CFP were treated with vehicle, TG, E2, or E2 + TG then fixed with 4% 
paraformaldehyde for 10 min at room temperature.  Each culture was assigned a 
random number that was unknown to the researcher to reduce bias.  Multiple images 
were collected and each cell was visually analyzed.  A cell was deemed positive for 
puncta if any puncta were visible.   
  Confocal Microscopy Assays.  A Leica SP5 confocal microscope with a 63X 
glycerol immersion objective was used for all confocal based assays.  Acceptor-
photobleaching FRET studies were performed on HEK293T cells expressing ESR1-
CFP, STIM1-YFP, and STIM1-mCherry as previously described [212].  Basal FRET was 
measured in cells that were treated with DMSO vehicle or 10 nM E2 for 15 m.  2 µM 
Thapsigargin was used to deplete ER-Ca2+ stores and FRET measurements were 
collected.  FRET images were analyzed using ImageJ.  The FRET efficiency (%E) was 
calculated as: ((donorpostbleach-donorprebleach)/donorpostbleach)*100.  Fluorescent recovery 
after photobleaching was measured in HEK293T cells expressing ESR1-mOr and YFP-
STIM1, YFP-STIM1570STOP, or YFP-STIM1S575A, unless stated otherwise.  Prebleach 
images were obtained before a circular region of interest was bleached.  Subsequent 
images were collected every 30 s until maximum recovery had occurred.  STIM1 FRAP 
curves were calculated by measuring the average fluorescence intensity in the bleached 
region of interest (ROI) per time point and dividing it by the average fluorescence 
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intensity of a non-bleached ROI within the same cell per time point.  To account for 
variations in protein expression and photobleaching, the average intensity ratio was 
normalized to the initial prebleach ratio. 
Immunoprecipitation and Western-blotting.  Immunoprecipitation was performed 
in HEK293T cells transfected with ESR1-mOrange and YFP-STIM1 or YFP-STIM1-
570STOP truncation mutant (STIM1570STOP).  Cells were lysed in 500 µl NP-40 lysis 
buffer (0.1% NP-40, 50 mM Tris-HCl, pH 7.4, 10 mM NaMoO4, 150 mM NaCl) 
supplemented with 1X complete EDTA-free protease inhibitors (Roche) and 2X Halt 
phosphatase inhibitor cocktail (Thermo).  Lysates were then centrifuged at 16,000g for 
10 min at 4°C and the supernatants were collected.  Protein concentrations were 
determined by the BCA protein assay kit (Pierce) and equal amounts of protein (600 µg) 
were diluted to 1.2 µg µl-1 with NP-40 lysis buffer in spin columns (Pierce) and mixed 
with anti-GFP polyclonal antibody (Abcam, 1:500) and rotated at 4°C overnight.  Protein 
A/G agarose beads (30 µl, Pierce) were added to lysate and rotated at 4°C for 4 hours.  
Beads were washed three times with NP-40 lysis buffer, centrifuged at 1000g for 2 
minutes at 4°C and protein was eluted by boiling in sample buffer (2X NuPAGE LDS 
sample buffer and 1X reducing agent (Life Technologies)).  Protein was resolved on a 4-
12% gradient NuPAGE Bis-Tris gels (Life Technologies) and transferred to nitrocellulose 
using iBlot (Life Technologies).  For western-blotting, immunoblots were blocked in 3% 
BSA in PBS-T for 1 h at room temperature, incubated overnight at 4°C with primary 
antibodies (anti-mpm-2, 1:500 (Millipore); anti-GFP 1:2000 (Abcam), and incubated with 
secondary antibodies (horseradish peroxidase-linked anti-mouse or ant-rabbit 1:10,000 
(GE Healthcare)) for 1 h at room temperature.  Proteins were detected using 
SuperSignal West Pico or Femto Chemiluminescent Substrate kit (Pierce). 
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Statistical Analysis.  All experiments were conducted on at least three separate 
occasions.  Data were analyzed using the method stated in the figure legend.  All 
statistical analyses were calculated using GraphPad Prism Software. 
3.4 Results 
E2 inhibits apical Ca2+ influx in human bronchial epithelial cells.   We have 
previously shown that E2 indirectly inhibits ligand-evoked Ca2+-activated Cl- secretion 
due to a reduction in Ca2+ signaling in human airway epithelia [167].  To test whether this 
depression of cytoplasmic Ca2+ was due to an E2-mediated reduction in SOCE, we 
performed Ca2+ imaging experiments in polarized, Fura-2 loaded HBECs.  HBECs were 
placed in Ca2+ free Ringer’s bilaterally and treated apically with thapsigargin (2 μM) to 
deplete ER Ca2+ (Fig. 3.1A).  Since E2 would physiologically reach the epithelium 
through the blood, we applied it basolaterally.  A 15 minute pretreatment with E2 (10 nM) 
had no effect on ER Ca2+ release (Fig. 3.1A).  We then added 2 mM Ca2+ to the apical 
surface to induce SOCE.  Cells that were pretreated with E2 displayed a significantly 
reduced change in the Fura-2 ratio emission upon Ca2+ addition relative to untreated 
cells, suggesting that basolateral E2 specifically inhibits apical Ca2+ entry in polarized 
HBECs without affecting ER Ca2+ release (Fig. 3.1A).   
Little is known regarding the molecular identity of the proteins involved in SOCE 
in the airway.  Therefore, we next determined if STIM1 and Orai1 were essential for 
SOCE in HBECs.  Non-polarized HBECs were transfected with STIM1, Orai1, or 
scrambled siRNA constructs or treated with vehicle (control).  qPCR measurements  
indicated that both genes were successfully knocked down (Fig. 3.1B).  We then 
performed Ca2+ imaging in these cells.  Non-polarized HBECs were placed in a Ca2+ free 
Ringer’s solution and stimulated with thapsigargin to specifically analyze ER Ca2+ 
dynamics.  Knockdown of STIM1 or Orai1 had no effect on ER Ca2+ release compared to 
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scrambled siRNA (Fig. 3.1C).  However, knockdown of either STIM1 or Orai1 completely 
abolished SOCE, whilst scrambled siRNA was without effect (Fig. 3.1C).  This indicated 
that STIM1 and Orai1 were essential for SOCE in HBECs.  While these observations 
were made in non-polarized HBECs, it is reasonable to assume that STIM1 and Orai1 
are necessary for SOCE in polarized HBECs. 
E2 inhibits translocation of STIM1 to the apical membrane in HBECs.  We have 
previously shown that GPCR-mediated IP3 formation and ER Ca
2+ release are 
unaffected by E2 [167].  Since STIM1 is next in the SOCE pathway, we tested whether 
this protein was sensitive to E2.  Under basal conditions, STIM1 was found be diffusely 
located in polarized HBECs (Fig. 3.2A).  However, after thapsigargin-induced ER Ca2+ 
depletion, STIM1 translocated towards the apical membrane.  HBECs that were 
basolaterally pretreated with E2 for 15 minutes displayed no difference in STIM1 
localization compared to untreated cells.  However, when ER Ca2+ was depleted in 
cultures pretreated with E2, STIM1 failed to translocate apically (Fig. 3.2A).  Data from 
several experiments were quantified by measuring STIM1 fluorescence intensity using 
an actin counterstain as a marker of polarity (Fig. 3.2B).  Analysis of this data revealed 
that the sub-apical concentration of STIM1 was significantly reduced after E2 exposure 
and suggested that E2 interrupted normal STIM1 function. 
E2 inhibits SOCE and STIM1 oligomerization in HEK293T cells.  To further study 
the effects of E2/ESR1 on STIM1 function, we performed additional experiments in 
HEK293T cells.  HEK293T cells were transfected with ESR1-mOrange because they do 
not endogenously express estrogen receptors [160].  As seen in HBECs, E2 did not 
affect ER Ca2+ release, but significantly reduced Ca2+ influx (Fig. 3.3A, B), suggesting 
that ESR1-transfected HEK293T cells were a valid model for studying the effects of 
E2/ESR1 on STIM1 function.   
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Oligomerization of STIM1 is an essential step in the initiation of SOCE after ER 
Ca2+ depletion [59, 213].  Therefore, we sought to determine if STIM1 oligomerization 
after ER Ca2+ depletion was inhibited by E2.  To characterize the effect of E2 on STIM1 
oligomerization, we performed fluorescence resonance energy transfer (FRET).  As a 
positive control, we linked YFP to mCherry with 5 glycines, which returned a FRET 
efficiency of ~42% using acceptor photobleaching, which is close to the theoretical 
maximum of 50% that can be measured with GFP-type proteins (n = 21).  Conversely, 
unlinked YFP and mCherry did not undergo FRET (n = 10).  We then performed FRET 
between STIM1-YFP and STIM1-mCherry in HEK293T cells.  N.B., these cells were also 
expressing ESR1-CFP.  However, this construct was only used to verify ESR1 
localization and was not excited during acceptor photobleaching.  In agreement with 
previous studies [59, 85-87], we found that STIM1-STIM1 FRET significantly increased 
after thapsigargin-induced ER Ca2+ depletion, suggesting that STIM1 had oligomerized 
(Fig. 3.3C, D).  A 15 minute pretreatment with E2 alone did not affect STIM1-STIM1 
FRET.  However, when cells were pretreated with E2 and then stimulated with 
thapsigargin, no significant increase in FRET was observed (Fig. 3.3C, D).  These data 
suggest that acute exposure to E2 inhibits STIM1 oligomerization. 
E2 disrupts STIM1 aggregation and redistribution.  Following oligomerization, 
STIM1 redistributes to the ER-plasma membrane junction where it interacts with Orai1 
and can been seen as puncta [59, 214].  In order to determine if E2 affects STIM1 
puncta formation, we transfected HEK293T cells with STIM1-mCherry and ESR1-CFP 
and collected images before and after ER Ca2+ depletion in the presence/absence of E2 
(Fig. 3.4A).  We did not observe STIM1 puncta under basal conditions, while after ER 
Ca2+ depletion, STIM1 formed puncta in ~90% of the cells (Fig. 3.4A, B).  E2 alone did 
not induce STIM1 puncta formation.  However, in the presence of E2, STIM1 puncta 
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formation was significantly decreased after ER Ca2+ depletion, suggesting that its ability 
to oligomerize had been impaired (Fig. 3.4A, B).   
We next performed FRET studies between STIM1 and Orai1.  Under control 
conditions, STIM1-Orai1 FRET significantly increased after ER Ca2+ depletion as 
previously described [86].  This indicated that STIM1 and Orai1 were in close proximity.  
However, this increase in FRET was abolished by a 15 minute E2 pretreatment, 
suggesting that E2 prevented STIM1 from interacting with Orai1 (Fig. 3.4C, D).  Because 
STIM1 oligomerization precedes the STIM1-Orai1 interaction, it is likely that loss of 
STIM1-Orai1 FRET in cells pretreated with E2 is a result of inhibiting STIM1 
oligomerization.  However, we cannot exclude the possibility that E2/ESR1 also affect 
Orai1. 
STIM1 mobility within the ER is inhibited by E2.  Because E2 impaired STIM1’s 
ability to oligomerize and interact with Orai1 (Figs. 3.3-3.4), we characterized the effects 
of E2 on STIM1 mobility.  Previous studies have utilized fluorescent recovery after 
photobleaching (FRAP) to demonstrate that STIM1 is highly mobile under basal 
conditions [59].  However, upon ER Ca2+ depletion, STIM1 mobility significantly 
decreases [59].  FRAP experiments were performed on HEK293T cells co-expressing 
YFP-STIM1 and ESR1-CFP (fluorescence not shown) (Fig. 3.5A).  Under basal 
conditions, we observed an ~80% recovery of STIM1 into the bleached area (Fig. 3.5B, 
C).  However, when ER Ca2+ was depleted with thapsigargin, the recovery of STIM1 
significantly decreased by ~50% postbleaching, indicating that STIM1 became less 
mobile (Fig. 3.5B, C), in agreement with previous reports [59, 215].  We then repeated 
this protocol on cells pretreated with E2.  Under basal conditions (i.e. with full ER 
stores), E2 significantly reduced STIM1 mobility (Fig. 3.5B, C), suggesting that E2 
exposure disrupts STIM1 mobility before STIM1 can sense changes in ER Ca2+ levels.  
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Following E2 exposure, thapsigargin only exerted a small additional effect on STIM1 
mobility (Fig. 3.5B, C).  To ensure that E2 inhibited STIM1 mobility through ESR1, we 
performed the same experiment on cells only expressing YFP-STIM1 but not ESR1 (Fig. 
3.5D, E).  Under these conditions, we found that E2 did not affect STIM1 mobility though 
the thapsigargin response was normal.  This coincides with our previous observation 
that E2 decreases cytoplasmic Ca2+ specifically through ESR1 in BHK cells [167].   
EB1 mobility is not affected by E2.  STIM1 translocates along microtubules by 
associating with the microtubule plus-end tracking protein EB1 [52].  Therefore, it is 
possible that the decrease in STIM1 mobility after E2 exposure was due to a decrease in 
EB1 mobility.  To test this, we performed FRAP studies on HEK293T cells co-expressing 
EB1-GFP and ESR1-CFP.  We found no change in EB1 mobility after ER Ca2+ depletion 
or exposure to E2 (Fig. 3.6).  These data suggest that E2/ESR1 is directly impacting 
STIM1, without affecting microtubule turnover. 
E2 inhibits basal phosphorylation of STIM1.  STIM1 contains several serine 
phosphorylation sites within its C-terminal domain that affect STIM1 function [64, 65].  To 
determine if E2/ESR1 exerted their influence on STIM1 by modulating the latter’s 
phosphorylation status, we used an anti-YFP antibody to immunoprecipitate YFP-STIM1 
from HEK293T cells that co-expressed ESR1.  The phosphorylation status of STIM1 was 
then probed using the mpm-2 antibody that specifically recognizes phosphorylated 
serines that are followed by a proline as previously described [65].  All known serine 
phosphorylation sites in STIM1 are followed by a proline; therefore the mpm-2 antibody 
should theoretically detect phosphorylation on every known serine phosphorylation site.  
Under basal conditions, we observed a distinct band at the predicted weight for YFP-
STIM1 (97 kDa, Fig. 3.7A), indicating that STIM1 was phosphorylated.  However, when 
cells were treated with E2, we observed a significant reduction in STIM1 phosphorylation 
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(Fig. 3.7A, B).  To determine where the phosphorylation site(s) were located, we 
measured phosphorylation in a STIM1 truncation mutant that terminated at amino acid 
570 (STIM1570STOP) [65].  We observed a significant reduction in phosphorylation basally 
and following E2 exposure with this mutant, indicating that the serine phosphorylation 
site was located towards the C-terminus of STIM1 (Fig. 3.7A, B).  The lack of 
phosphorylation with STIM1570STOP also acted as a control to confirm that the YFP tag 
was not being phosphorylated.  Because we observed a decrease in phosphorylation 
after E2 pretreatment, we hypothesized that basal phosphorylation was being inhibited.  
Serines 575, 608, and 621 are phosphorylated and are required to allow activation of 
SOCE [64].  As a first step toward testing whether these serines were affected by 
E2/ESR1, we constructed a YFP-STIM1 point mutant where serine 575 was mutated to 
an alanine (STIM1S575A).  Basal phosphorylation of STIM1S575A was significantly 
decreased compared to WT STIM1 (Fig. 3.7A, B).  Importantly, there was no further 
decrease in phosphorylation of STIM1S575A when exposed to E2.  Additional point 
mutants at Ser 608 and Ser 621(i.e. STIM1S575/608/621A) did not decrease STIM1 
phosphorylation further (data not shown), suggesting that Ser 575 is the phosphorylation 
site that is affected by E2/ESR1.   
We next performed FRAP studies on STIM1S575A to determine if removal of this 
phosphorylation site affected STIM1 mobility (Fig. 3.7C, D).  STIM1S575A was significantly 
less mobile than WT STIM1 under basal conditions (Fig. 3.7D).  Furthermore, treatment 
with thapsigargin or E2 had no additional effect on STIM1S575A mobility.  These data 
suggest that loss of STIM1 phosphorylation at Ser 575 by E2/ESR1 induces impaired 
STIM1 mobility leading to reduced SOCE.  The mobility of the triple point mutant, 
STIM1S575/608/621A, was not different from STIM1S575A (data not shown).  Overall, these 
data indicate that phosphorylation of Ser 575 is crucial for normal STIM1 function and 
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that a change in STIM1’s phosphorylation status by E2/ESR1 is a mode of regulation for 
this protein. 
 
3.5 Discussion 
Many biological processes are initiated by rises in Ca2+.  Thus, regulation of 
intracellular Ca2+ levels is extremely important for normal cellular function [208].  We 
have previously shown that E2 inhibits Ca2+ activated Cl- secretion in airway epithelia by 
obstructing Ca2+ influx [167]; however, the pathway utilized by E2 to disrupt this process 
was not known.  Here, we show that acute exposure to E2 inhibits translocation of 
STIM1 to the apical membrane region in polarized HBECs after ER Ca2+ depletion (Fig. 
2).  Together with calcium imaging experiments in polarized HBECs (Fig. 3.1), our 
findings suggest that SOCE occurs at the apical membrane in polarized HBECs and is 
specifically inhibited by E2.  These findings complement previously published data that 
indicated that SOCE can occur at the apical membrane in nasal epithelial cells [216].  
Paradiso et al. demonstrated that Ca2+ influx was itself polarized and was ipsilateral to 
the stimulus [216].   
Previous studies have shown that under resting conditions, STIM1 exists as a 
dimer that oligomerizes into a higher order complex immediately after ER Ca2+ depletion 
[59, 217].  Several studies have utilized FRET to measure oligomerization [59, 214].  An 
increase in FRET efficiency after ER Ca2+ depletion is suggestive of STIM1 
oligomerization.  However, FRET only shows proximity and does not confirm an 
interaction.  In our studies, we found that acute exposure to E2 inhibited the 
thapsigargin-mediated FRET increase, suggesting that oligomerization was hindered 
(Fig. 3.3).  It is important to note that E2 alone had no effect on STIM1-STIM1 FRET 
under resting conditions; however STIM1 mobility was significantly decreased (Fig. 3.5), 
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suggesting that the resting oligomeric structure of STIM1 was not affected by E2.  
Therefore, it is possible that E2 only affects STIM1 aggregation after ER Ca2+ depletion 
and not the resting oligomeric structure.  Following oligomerization, STIM1 translocates 
to the ER-plasma membrane junction where it aggregates into distinct puncta and 
interacts with Orai1.  Our results indicated that E2 inhibited the formation of puncta after 
ER Ca2+ depletion, which coincided with a decrease in STIM1-Orai1 FRET (Fig. 3.4).  
Since STIM1 oligomerization precedes puncta formation and the STIM1-Orai1 
interaction, it is likely that the observations in Fig. 4 are a result of inhibiting STIM1 
oligomerization.  
In our FRAP studies, we observed a significant decrease in the mobile fraction of 
STIM1 after thapsigargin-induced ER Ca2+ depletion, which is consistent with previously 
published data [59].  This finding may be due to STIM1 aggregates interacting with the 
plasma membrane and/or Orai1.  To our surprise, E2 alone decreased the mobile 
fraction of STIM1 without inducing puncta formation.  Because STIM1 aggregation 
precedes translocation to the ER-plasma membrane junction, it is unlikely that E2 
decreased STIM1 mobility by inducing a plasma membrane interaction.  However, it is 
possible that E2 altered a STIM1 protein interaction that decreased mobility under 
resting conditions.  Several studies have shown that cytoskeletal proteins, such as 
tubulin and actin, can interact with or impact STIM1 function [52, 61, 67, 218].  Previous 
studies have shown that the microtubule plus-end tracking protein EB1 links STIM1 to 
the microtubule network and is likely involved in reorganizing the ER [52, 67].  Therefore, 
it is possible that E2/ESR1 was impacting EB1 function and not STIM1.  However, our 
FRAP studies indicated that E2/ESR1 had no effect on EB1 mobility, suggesting a more 
direct impact on STIM1 (Fig. 3.6).  Nevertheless, it is possible that E2 could affect 
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interactions between STIM1 and the cytoskeleton to inhibit mobility under resting 
conditions.   
Several recent studies have shown that phosphorylation can regulate STIM1 and 
SOCE [64, 65, 67].  For example, during mitosis, SOCE is inhibited by phosphorylating 
STIM1 on Ser 486 and Ser 668 [65].  Conversely, phosphorylation of STIM1 on Ser 575, 
Ser 608, and Ser 621 is required for SOCE [64].  This suggests that the site of 
phosphorylation can greatly influence STIM1 function.  In our studies, we found that 
E2/ESR1 inhibited basal phosphorylation of STIM1 on Ser 575.  Furthermore, mutation 
of this residue to an alanine significantly decreases STIM1 mobility (Fig. 3.7A, B), 
replicating the effects of E2/ESR1.  However, we cannot rule out the possibility that other 
serine phosphorylation sites are being affected by E2/ESR1, but may not be detectable 
with the mpm-2 antibody.  Furthermore, the exact mechanism utilized by E2/ESR1 to 
inhibit phosphorylation remains unknown.  Estrogen receptors have typically been 
described as regulators of gene transcription [159].  However, it is well established that 
estrogen receptors can also signal nongenomically [159, 162].  For example, signaling 
through ESR1 has been shown to impact the PI3K/Akt and ERK1/2 cascades [162, 164].  
Conversely, E2/ESR1 may activate a phosphatase to dephosphorylate STIM1. 
Gender is a risk factor for most lung diseases, including asthma, CF, and COPD.  
Bronchoconstriction [219], mast cell degranulation [220] and mucus hypersecretion [221] 
are characteristics of asthma that are Ca2+-regulated and E2/ESR1 has been shown to 
act as a bronchodilator in human airway smooth muscle cells by decreasing intracellular 
Ca2+ levels [146].  This suggests that E2 is airway protective in asthma.  However, there 
are many other characteristics of asthma that may be affected by E2/ESR1, including 
airway smooth muscle hyperplasia and hypertrophy, goblet cell hyperplasia, and 
inflammation.  Chronic obstructive pulmonary disease (COPD) also disproportionately 
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affects women and 80% of early onset COPD patients are female [149].  Characteristics 
of COPD include abnormal ion transport, goblet cell hyperplasia and mucus dehydration 
[222].  Women with CF are also known to suffer more severely than their male 
counterparts [134-136, 223], have a higher mortality [134, 135], and are more likely to 
experience acute exacerbations when E2 is highest during the peri-ovulatory period 
[136, 223].  Sex differences such as those seen in asthma, COPD and CF are likely to 
be very complex.  However, E2/ESR1-mediated inhibition of STIM1 may play a role in 
affecting the severity of all of these diseases.  In the case of bronchoconstriction, 
reduced Ca2+ levels may be protective.  Conversely, in the case of altered ion transport, 
limiting CaCC activity by decreasing Ca2+ may further impair the ability to hydrate the 
airways, and so may exacerbate the disease in females [14]. 
In conclusion, we have demonstrated that E2/ESR1 can inhibit SOCE by 
regulating STIM1 function.  Under normal conditions, phosphorylated STIM1 can sense 
ER Ca2+ depletion, oligomerize and activate Orai1 (Fig. 3.7E).  However, we propose 
that acute E2 exposure activates ESR1, which signals non-genomically, to inhibit basal 
phosphorylation of STIM1 (Fig. 3.7E, F).  Consequently, STIM1 is unable to oligomerize 
after ER Ca2+ depletion and fails to activate Orai1, leading to a decrease in SOCE.  A 
better understanding of this process may lead to the development of novel therapeutic 
strategies to reverse the sex bias in chronic lung disease. 
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Figure 3.1.  STIM1-dependent Ca2+ influx in HBECs is inhibited by E2.  A, Mean 
changes in Fura-2 emission ratio in polarized HBECs under control conditions or 
exposed to 10 nM E2 for 15 min.  HBECs were placed in bilateral Ca2+ free Ringers and 
stimulated with 2 µM thapsigargin to monitor ER Ca2+ depletion.  2 mM Ca2+ was added 
back to the Ringers solution on the apical surface only to induce SOCE.  B, Relative 
expression of STIM1 or Orai1 after siRNA knockdown, as indicated by qPCR.  Non-
polarized HBECs were treated with transfection reagent alone (Ctrl) or transfected with 
scrambled (Scr) or targeted knockdown (KD) siRNA constructs.  C, Fura-2 emission ratio 
in non-polarized HBECs that were transfected with scrambled, STIM1, or Orai1 siRNA 
constructs.  SOCE was measured by adding extracellular Ca2+ back to the Ringer’s after 
ER Ca2+ depletion with 2 μM thapsigargin.  Error bars represent mean ± S.E.M.  TG, 
thapsigargin.  This work was completed with Michael J. Watson 
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Figure 3.2.  E2 inhibits thapsigargin-induced STIM1 translocation in HBECs.  A, 
Typical XZ confocal micrographs of STIM1 immunocytochemistry (red) with actin 
counterstain (phalloidin, green).  Representative images were from one of several 
experiments.  The cells were either untreated (basal), stimulated with thapsigargin (2 
μM) to deplete ER Ca2+, with E2 (10 nM), or with E2 and thapsigargin.  B, Graph of 
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mean pixel intensity of STIM1 in relationship to the apical membrane.  Error bars 
represent mean ± S.E.M.  Scale bar represents 25 μm.  TG, thapsigargin. 
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Figure 3.3. E2/ESR1 inhibits SOCE and STIM1 oligomerization in HEK293T cells.  
A, Typical changes in Fura-2 emission ratio in HEK293T cells acutely exposed to vehicle 
or E2 in Ca2+ free Ringers solution and when 2 mM Ca2+  was added back to the Ringers 
solution.  B, Mean differences in Fura-2 emission ratio taken from A.  ‘*’ indicates a 
significant difference (unpaired t-test; p = 0.0049).  Control (white bars), both n = 53; E2 
(black bars), both n = 57.  C, Typical confocal micrographs of STIM1-YFP (green, donor) 
and STIM1-mCherry (red, acceptor) before and after photobleaching of STIM1-mCherry 
in control cells under basal conditions.  Cells were also expressing ESR1-CFP (not 
shown).  D, Mean STIM1-STIM1 FRET efficiency (%E) in HEK293T cells. Ctrl, basal n = 
31; Ctrl, thapsigargin n = 35; E2, basal n = 26; E2, thapsigargin n = 25.  ‘*’ indicates a 
significant difference (one-way ANOVA followed by Tukey’s multiple comparison test; p 
< 0.001).  Error bars represent mean ± S.E.M.  Scale bars represent 10 μm.  TG, 
thapsigargin.  
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Figure 3.4.  E2 inhibits STIM1 aggregation and redistribution.  A, Typical images of 
STIM1-mCherry (red) and ESR1-CFP (cyan) in HEK293T cells under control or E2 
pretreatment conditions ± thapsigargin.  B, Percent HEK293T cells containing STIM1 
puncta.  Ctrl, basal n = 46; Ctrl, TG n = 47; E2, basal n = 45; E2, TG n = 48.  C, Typical 
confocal micrographs of Orai1-YFP (green, donor) and STIM1-mCherry (red, acceptor) 
before and after photobleaching of STIM1-mCherry in control cells under resting 
conditions.  Cells were also expressing ESR1-CFP (not shown).  D, Mean STIM1-Orai1 
FRET efficiency (%E) in HEK293T cells.  Ctrl, basal n = 39; Ctrl, TG n = 31; E2, basal n 
= 39; E2, TG n = 33.  ‘*’ indicates a significant difference (one-way ANOVA followed by 
Tukey’s multiple comparison test; p < 0.001).  Error bars represent mean ± S.E.M.  
Scale bars represent 10 μm.  TG, thapsigargin.  
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Figure 3.5. E2/ESR1 inhibits STIM1 mobility.  A, Typical images of YFP-STIM1 in 
HEK293T cells before and after photobleaching YFP-STIM1.  Dashed circles indicate 
the area that was bleached.  B, Normalized recovery of YFP-STIM1 after photobleaching 
in HEK293T cells co-expressing ESR1-CFP (not shown) under basal conditions (n = 15) 
and after thapsigargin stimulation (n = 13) or when pretreated with E2 (n=17) and after 
E2 with thapsigargin (n = 16).  C, Mobile fraction of YFP-STIM1 in HEK293T cells co-
expressing ESR1 under each condition.  D, Normalized recovery of YFP-STIM1 after 
photobleaching in HEK293T under basal conditions (n = 13) and after thapsigargin 
stimulation (n=10) or when pretreated with E2 (n = 9) and after thapsigargin stimulation 
(n = 10).  E, Mobile fraction of YFP-STIM1 in HEK293T cells under each condition.  ‘*’ 
indicates a significant difference of p < 0.05 and ‘**’ indicates a significant difference of p 
< 0.001 (one-way ANOVA followed by Tukey’s multiple comparison test).  Error bars 
represent mean ± S.E.M.  Scale bar represents 10 μm.  TG, thapsigargin. 
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Figure 3.6. E2 does not alter EB1 mobility.  Bar graph shows the mobile fraction of 
EB1-GFP in HEK293T cells after photobleaching.  Cells also expressed ESR1-CFP.  All 
conditions, n = 8.  Error bars represent mean ± S.E.M.   
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Figure 3.7.  Inhibition of STIM1 phosphorylation decreases STIM1 mobility.  A, WT 
YFP-STIM1, STIM1570STOP, and STIM1S575A were immunoprecipitated from HEK293T 
cells co-expressing ESR1.  Membranes were probed with the mpm-2 antibody that 
specifically recognizes phosphorylated serines. The blot was stripped and reprobed with 
a GFP antibody to reveal total immunoprecipitated STIM1.  B, Relative density of STIM1 
phosphorylation for each STIM1 construct under basal conditions or after E2 treatment.  
Relative density for phosphorylated STIM1 was calculated by normalizing to total 
immunoprecipitated STIM1 and comparing it to WT STIM1 under basal conditions.  YFP-
STIM1, n = 11; STIM1570STOP, n = 4; STIM1S575A, n = 6.  C, Mean recovery of STIM1S575A 
into the bleached area following FRAP.  Basal, n = 19; thapsigargin, n = 12; E2, n = 11; 
E2 + thapsigargin, n = 10.  D, Mobile fraction of STIM1S575A after photobleaching (black 
bars) compared to WT STIM1 (white bars).  All FRAP data were collected concurrently.  
‘*’ indicates a significant difference of p <0.05 and ‘**’ indicates a significant difference of 
p < 0.001(one-way ANOVA followed by Tukey’s multiple comparison test).  Error bars 
represent mean ± S.E.M.  TG, thapsigargin.  E, Model depicting SOCE after ER Ca2+ 
depletion in the absence of E2.  Phosphorylated STIM1 oligomerizes and interacts with 
Orai1 to induce SOCE.  Elevations in cytoplasmic Ca2+ then lead to activation of CaCC.  
F, Proposed model of E2/ESR1-mediated inhibition of STIM1 and SOCE after ER Ca2+ 
depletion.  E2/ESR1 inhibits STIM1 phosphorylation via an unknown mechanism.  This 
inhibits STIM1 oligomerization, redistribution, and interaction with Orai1 to block SOCE.  
Low cytoplasmic Ca2+ reduces CaCC activation.  
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Chapter IV 
General Discussion 
 
 
4.1 Overview of Results 
 The goal of the research presented in this dissertation is to advance our 
understanding of the physical and functional properties of Ano1/CaCC.  Ca2+-activated 
Cl- currents have been observed in numerous cells types and tissues, including the 
airways where it is involved in regulating ASL hydration.  In CF airways, which lack 
CFTR, CaCC is still present and could be therapeutically targeted to compensate for the 
loss of CFTR-mediated Cl- secretion.  However, the molecular identity of CaCC 
remained unknown until 2008, when Ano1 was proposed as the gene/protein underlying 
CaCC [105-107].  Since then, there has been a surge of interest in the physical and 
structural properties of Ano1.  A common property of many ion channels is the ability to 
oligomerize, but it was unknown if Ano1 underwent this process.  Thus, the goal of 
chapter 2 was to determine the oligomeric structure of Ano1 and, if it does oligomerize, 
the number of interacting subunits.   
 It has been extensively documented that female CF patients suffer more 
severely than their male counterparts [134, 135].  There are likely many factors 
influencing CF pathogenesis in females, but sex hormones are likely involved.  Previous 
studies from our laboratory have demonstrated that elevated levels of estrogen inhibit 
CaCC by blocking SOCE in a non-genomic fashion in the airways [167].  However, very 
little is known about the players involved in this process.  Thus, in chapter 3, we 
investigated the effects of E2/ESR1 on signaling proteins upstream of CaCC activation. 
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4.2 Chapter 2 Overview: Ano1 Oligomerization 
  The research presented in chapter 2 of this dissertation addressed the 
oligomeric structure of Ano1.  To probe the quaternary structure of Ano1, we employed 
several biochemical and microscopy based techniques.  We chose to conduct our 
studies in HEK293 cells since they do not have an endogenous Ca2+-activated Cl- 
current [194], which was confirmed with RT-PCR.  While Ano1 was not detected, we did 
observe expression of several other Ano family members (Ano2, 4, 5, 6, 10).  
Interestingly, both Ano2 and 6 were detected, which have been shown to form Cl- 
channels [110, 111].  Nevertheless, our data indicated that Ano2 and 6 are unable to 
form functional plasma membrane Cl- channels in HEK293 cells, suggesting a cell-
specific function.  HEK293 cells were then transfected with Ano1 constructs (tagged and 
untagged) and whole-cell patch clamping was performed.  The electrophysiological 
properties of tagged Ano1 were not altered compared to untagged Ano1.  These results 
indicated that the addition of a fluorescent tag had no apparent effect on Ano1 function 
(experiments conducted by Dr. Kuai Yu and Dr. Criss Hartzell).   
We then performed FRET experiments to determine if Ano1 molecules are in 
close proximity to each other.  A significant FRET signal was observed between Ano1 
molecules, but not with other membrane proteins that are important for ASL secretion, 
such as CFTR and A2BR.  Additionally, Ano1 FRET was not affected by changes in 
intracellular Ca2+.  Also, our results indicated that Ano1 oligomerization and trafficking to 
the plasma membrane were not dependent on the actin cytoskeleton.  Since completion 
of this work, it has been shown that Ano1 associates with the actin cytoskeleton through 
the ERM proteins, which can affect Ano1 activity [121].  One downside of FRET is that it 
cannot confirm a direct interaction and only shows proximity or a change in orientation of 
the fluorophores.  Therefore, we performed additional biochemical experiments to 
confirm the interaction and identify the oligomeric structure.  Chemical-cross linking, 
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non-denaturing gel electrophoresis, and electromobility shift assays revealed that Ano1 
oligomerizes as a dimer.  Our chemical-cross linking experiments suggested that higher 
order oligomers may exist, but these were not observed using non-denaturing gel 
electrophoresis.  One potential caveat to our data is that we were overexpressing Ano1; 
therefore, the observed higher order oligomers may not occur naturally.  However, it 
remains possible that under certain conditions Ano1 could enter into larger complexes.  
In fact, a recent study examined Ano1’s interactome and identified over 200 proteins that 
associate with Ano1 [121]. 
Since this study was published, it has been cited numerous times and has 
influenced research within the field.  Our finding that Ano1 is a dimer raised additional 
questions: Is dimerization required for channel function?  What domains within Ano1 
mediate dimerization?  A recently published study addressed these exact questions.  
They specifically identified a region within the N-terminus of Ano1 that facilitates 
dimerization, which contains a series of amino acids (19 in total) that are necessary for 
assembly [224].  Furthermore, they determined that Ano1 dimerization is necessary for 
function [224]. 
 
4.3 Chapter 3 Overview: Estrogen Inhibits STIM1 
In chapter 3, we conducted experiments to identify the mechanism utilized by 
estrogen to inhibit Ca2+ influx and ultimately CaCC.  We found that acute exposure to E2 
inhibited translocation of STIM1 to the apical membrane in polarized HBECs.  This, in 
itself, is a significant finding, because endogenous STIM1 had never been previously 
imaged in polarized airway cells.  Together with calcium imaging experiments in 
polarized HBECs, our findings suggested that SOCE occurs at the apical membrane in 
polarized HBECs and is specifically inhibited by E2.  These findings complement 
previously published data that indicated that SOCE can occur at the apical membrane in 
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airway epithelial cells [216].  Furthermore, this study also demonstrated that Ca2+ influx 
was restricted to the membrane region that was stimulated.  Thus, if the basolateral 
region was stimulated to induce ER Ca2+ depletion, then Ca2+ influx would occur at the 
basolateral membrane.  Furthermore, it has been shown that mitochondria are 
responsible for this Ca2+ compartmentalization by acting as barriers that can take up 
cytoplasmic Ca2+, preventing Ca2+ diffusion [225].  In our studies, we only examined the 
effects of E2 on apical Ca2+ influx, because nucleotides that are released into the 
airways would impact the apical surface.  Furthermore, we speculate that if Ca2+ entered 
basolaterally it would be unable to diffuse through the cell to the apical membrane where 
CaCC is located due to the mitochondrial barrier.  
To better study the effect of E2 on STIM1, we performed several microscopy 
based experiments in HEK293T cells expressing fluorescently tagged constructs.  FRET 
experiments indicated that E2 disrupted STIM1 oligomerization after ER Ca2+ depletion.  
We also performed experiments where puncta formation was quantified and we found 
that E2 inhibits puncta formation after ER Ca2+ depletion.  Additionally, acute exposure 
to E2 significantly decreased STIM1-Orai1 FRET after ER Ca2+ depletion.  Since STIM1 
oligomerization precedes the STIM1-Orai1 interaction, it is likely that the loss of STIM1-
Orai1 FRET in cells pretreated with E2 was a result of E2/ESR1 inhibiting STIM1 
oligomerization.  However, we cannot exclude the possibility that E2/ESR1 also affected 
Orai1 directly.  Activation of protein kinase C (PKC) induces phosphorylation of Orai1 at 
Ser 27 and Ser 30 to inhibit SOCE [226].  Thus it is possible that Orai1 phosphorylation 
may increase after E2 exposure to inhibit SOCE.   
We also performed FRAP experiment to measure STIM1 mobility, since E2 
disrupted STIM1 aggregation and translocation.  After ER Ca2+ depletion, YFP-STIM1 
mobility significantly decreased as previously described [59].  In cells co-expressing 
ESR1, acute exposure to E2 significantly decreased YFP-STIM1 mobility, prior to ER 
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Ca2+ depletion. Importantly, in the absence of ESR1 co-expression, E2 had no effect on 
YFP-STIM1 mobility, indicating that the inhibitory actions of E2 were mediated by ESR1. 
STIM1 contains several serine phosphorylation sites within its C-terminal domain 
that affect STIM1 function [64, 65], such as serines 575, 608, 621, which are basally 
phosphorylated [64].  Our results indicated that E2/ESR1 inhibited basal phosphorylation 
of STIM1.  When Ser 575 was mutated phosphorylation was abolished and exposure to 
E2 had no further effect.  Thus, we concluded that E2/ESR1 was inhibiting SOCE and 
CaCC activity by blocking phosphorylation or inducing dephosphorylation of Ser 575.  
However, we cannot exclude the possibility that Ser 608 and Ser 621 are being affected 
by E2/ESR1.  It is entirely possible that the phospho-specific antibody we were using, 
which recognizes phosphorylated serines, was unable to detect every single site.  
Furthermore, we do not know the mechanism utilized by E2/ESR1 to decrease basal 
phosphorylation.  E2/ESR1 has been shown to impact several signaling cascades, such 
as the PI3K/Akt and ERK1/2 pathways.  Therefore, it is possible that inhibition of STIM1 
phosphorylation is mediated through one of these pathways.  Another possible 
explanation for the loss of STIM1 phosphorylation is that a phosphatase was activated 
by E2/ESR1.  Thus further needs to be completed to determine the mechanism utilized 
by E2/ESR1 to inhibit STIM1 phosphorylation.    
.   
4.4 Future Work 
While we have conclusively shown that Ano1 exists as a dimer, our experiments 
were conducted in HEK293 cells overexpressing fluorescently tagged Ano1 constructs.  
During our chemical cross-linking experiments we observed very faint bands at high 
molecular weights that could correspond to a trimer, tetramer, or a hetero-oligomer.  
These bands were not detected after non-denaturing gel electrophoresis experiments.  
Still, it is possible that Ano1 could enter into larger complexes, which may be transient in 
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nature.  However, because our experiments were conducted in an overexpression 
system, where localization of Ano1 to the plasma membrane was abundant, the plasma 
membrane may have been “overcrowded”.  Thus, the higher order bands may be due to 
cross-linking closely associated proteins to Ano1. Therefore, it would be interesting to 
determine if endogenous Ano1 is able to form these higher order bands.   HEK293 cells 
do not express Ano1 endogenously [212], therefore an alternative cell type would need 
to be utilized to perform these experiments, such as airway epithelial cells.   
It is also possible that Ano1 could enter into a heteromeric complex with other 
Ano family members.  There have been conflicting reports on the cellular location and 
functional properties of the other Ano proteins [112, 115].  The study by Tian et al. 
examined the effect of co-expressing Ano1 with Ano4, 6, 7, 9, or 10 and concluded that 
co-expressing Ano9 inhibited ATP-mediated activation of Ano1 [112], suggesting that 
Ano1 and 9 specifically interact.  However, they did not examine the subcellular 
localization of these proteins when co-expressed and therefore, cannot conclusively 
conclude that Ano1 and 9 interact.  In order to determine if Ano1 oligomerizes with other 
Ano proteins we can perform experiments similar to those conducted in Chapter 2.  
Specifically, Ano1 and the other Ano family members could be fluorescently tagged and 
overexpressed in HEK293 cells to determine if Ano1 influences the subcellular 
localization of the other Ano proteins and whether there is a direct association.  Along 
with Ano1 spice variants; this may help explain why there are variations in the 
electrophysiological properties of CaCC between cell types [117, 227-230]. 
Regulation of Ano1 is not fully understood.  Specifically, it is unclear if Ca2+ 
directly binds to Ano1 or whether a Ca2+ sensing protein confers sensitivity to Ca2+. A 
recent study by Tian et al. suggested that calmodulin is necessary for Ano1 function in 
HEK293 cells [120] even though Ano1 does not contain a canonical calmodulin binding 
domain [99].   Calmodulin is a small protein consisting of two globular ends that contain 
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two EF-hand motifs that bind Ca2+ with high affinity and can interact and activate 
additional signaling proteins [231].  This study showed that calmodulin bound to a 
domain that overlaps with segment b of abc-Ano1.  Additionally, in the absence of 
segment b, the association between Ano1 and calmodulin was abolished.  Conversely, 
studies by Ferrera et al. have shown that ac-Ano1 requires less Ca2+ to be activated 
[117].  Furthermore, deleting amino acids 448EAVK (segment c) in the first cytoplasmic 
loop drastically decreases apparent Ca2+ affinity [119], suggesting that segment c 
confers sensitivity to Ca2+.   
To determine if Ano1 directly binds Ca2+, we would perform 45Ca2+ overlay 
assays.  This technique has been previously used to identify the “Ca2+ bowl” in the BK 
channel [118].  Ano1 or Ano1 fragments could be purified to perform 45Ca2+ overlays 
assays to determine if Ca2+ directly binds.  Specifically, Ano1 would be tagged with 
maltose binding protein and expressed in bacteria.  Maltose binding protein binds 
amylose resin which enables it to be purified on a column.   The maltose binding protein 
tag can then be cleaved off to obtain purified Ano1/Ano1 fragments, which would then be 
run on a non-denaturing gel.  Following transfer to a nitrocellulose membrane, the blot 
would be incubated with 45CaCl2, dried, and finally exposed to film to determine if 
45Ca2+ 
bound.  As positive controls, purified calmodulin and calpain could be run alongside 
Ano1.  Both calmodulin and calpain contain four EF hand Ca2+-binding motifs that will 
bind 45Ca2+.  As a negative control, bovine trypsin could be used, because it does not 
bind Ca2+ [118].  This technique would allow us to conclusively determine whether Ano1 
can directly bind Ca2+. 
Our results indicated that Ano1 trafficking was not disrupted after depolymerizing 
the actin cytoskeleton with cytochalasin D.  Also, it was recently shown that knocking 
down moesin, a protein that is associated with the actin cytoskeleton, did not affect Ano1 
surface expression, but did decrease Ano1 activity, suggesting a regulatory role for the 
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cytoskeleton [121].  Based on sequence analysis, Ano1 is predicted to contain 
phosphorylation sites for several kinases, including protein kinases A and C [232].  
Furthermore, Ano1 has been shown to interact with kinases and other regulatory 
proteins [121].  However, very little research has been conducted regarding Ano1 
phosphorylation.  Thus, it would be interesting to determine if phosphorylation affects 
Ano1 function and, if it does, whether the actin cytoskeleton is involved. 
In Chapter 3, we determined that acute exposure to estrogen inhibits STIM1 
phosphorylation, which disrupts normal function and prevents SOCE.  Our 
phosphorylation experiments were conducted on HEK293 cells overexpressing 
fluorescently tagged STIM1.  However, it is important to determine if phosphorylation on 
endogenous STIM1 is also inhibited by estrogen.  Using a STIM1-specific antibody, 
endogenous STIM1 can be immunoprecipitated from HEK293 cells and probed with the 
mpm-2 antibody, to determine STIM1’s phosphorylation status.  Furthermore, it would be 
interesting to determine if STIM1 phosphorylation is altered in human tissue when 
estrogen levels are elevated.  Females volunteers would be recruited to collect nasal 
biopsies when circulating estrogen levels are both low and elevated (i.e. during menses 
and ovulation).  Endogenous STIM1 can then be immunoprecipitated to probe the 
phosphorylation status. 
Finally, the exact mechanism utilized by E2/ESR1 remains unknown.  Our 
findings support a non-genomic mechanism, where activation of ESR1 impacts a 
signaling cascade to block STIM1 phosphorylation or activate a phosphatase that 
removes phosphorylation.  Several studies have shown that ESR1 signals non-
genomically to impact the PI3K/Akt and ERK1/2 cascades [162, 164].  Additionally, 
STIM1 is known to contain several ERK1/2 phosphorylation sites, including Serine 575 
[64].  Therefore, we speculate that E2/ESR1 may impact one of these pathways to inhibit 
STIM1 phosphorylation.  When active, both Akt and ERK1/2 are phosphorylated [233], 
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therefore phospho-specific antibodies to these proteins could be used to determine if 
estrogen/ESR1 affects either pathway.   
Furthermore, inhibitors that specifically block the PI3K/Akt and ERK1/2 pathways 
can be used in combination with estrogen to determine if the phosphorylation status of 
STIM1 is affected.  However, there are limitations to this approach.  Many inhibitors are 
not completely specific and have off target effects, but this problem can be mitigated by 
performing the experiments with several different inhibitors.  Also, it has been shown that 
phosphoinositides, such as PIP2, are important for STIM1 oligomerization and 
translocation to the ER-plasma membrane junction [234].  Inhibiting PI3K activity 
depletes phosphoinositides from the plasma membrane and, due to the effects on 
STIM1, can block SOCE.  This may make it difficult to measure the functional impacts of 
blocking PI3K on STIM1.  However, it may be possible to inhibit the downstream target 
of PI3K, Akt, using an allosteric Akt inhibitor [235].   
Finally, with advances in medicine, CF women are surviving well into their 
reproductive years and are using contraceptives to prevent pregnancy [134, 236].  Our 
studies have shown that CaCC is inhibited by estrogen [167]; therefore, it is possible that 
the estrogen in hormonal birth control could inhibit CaCC.  This would be detrimental for 
female CF patients because CaCC would be inhibited indefinitely, which may increase 
ASL dehydration.  A common type of estrogen in birth control is ethinyl estradiol (EE), 
which is a derivative of E2.  To determine if EE also inhibits CaCC, we measured nasal 
potential differences in normal female patients who are on EE-based birth control versus 
control female patients with low E2 levels (i.e. during menstruation).  We found that EE-
based birth control had no effect on CFTR and ENaC; however, CaCC was significantly 
inhibited when compared to control patients (Fig. 4.1).  This suggests that EE inhibits 
CaCC in vivo and may be detrimental to female CF patients.  However, additional work 
needs to be conducted to determine what the effects of EE are on ASL hydration.  
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Furthermore, determining the dose-response curve for EE is necessary to determine the 
minimum dosage that can inhibit CaCC.   
 
4.5 Clinical Implications 
 New strategies for treating CF have been plentiful.  With the discovery of cftr as 
the defective gene in CF, the idea of employing gene therapy was developed.  Multiple 
clinical trials were conducted with various levels of success.  However, to date, there 
have been no studies using gene therapy that have corrected the underlying genetic 
defect [237].  Thus, gene therapy has been largely abandoned as a viable treatment 
option and emphasis has now been placed on designing compounds that will correct 
cellular function.  There is a large emphasis on developing corrector and potentiator 
compounds.  These compounds would enable mutant CFTR to traffic to the plasma 
membrane and function normally.  One such potentiator, known as ivacaftor, has been 
remarkably successful for the treatment of patients with the G551D CFTR mutation and 
is now widely used [238].  However, only a small percentage of patients with CF have 
the G551D mutation.  Developing compounds that prevent hyperabsorption of Na+ 
through ENaC are also being explored [11, 239].  Inhaled hypertonic saline is now a 
routine treatment, which osmotically draws water into the airways to loosen up mucus 
[240].  However, this is just a temporary solution and hypertonic saline needs to be 
administered 2-3 times a day.  Thus, continued research into new drugs is necessary to 
combat CF.   
Another method to prevent ASL dehydration is to target other Cl- channels 
already present in the airways.  One such channel is CaCC.  Secretion of Cl- through 
CaCC can be easily achieved by activating the P2Y2 receptor to raise intracellular Ca
2+.  
Typical P2Y2 agonists, such as ATP and UTP are readily broken down by 
ectonucelotidases, so a compound known as Denufusol that is resistant to breakdown 
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was developed and tested in clinical trials.  However, this compound did not significantly 
improve lung function in patients with CF [132].  Denufusol may have failed due a short 
half-life in vivo, which was measured to be 17 minutes.  The observed in vivo half-life 
was significantly shorter than the 25 hour half-life seen in ex vivo CF sputum.  This 
suggested that ectonucleotidases, which are upregulated in CF airways, degraded 
Denufusol.  With the discovery that Ano1 is an essential subunit of CaCC [105-107], 
compounds that directly target Ano1 can be developed to increase Cl- secretion.  
However, in order to develop effective therapies, it is essential that Ano1’s structure and 
gating are fully understood.  Our findings in chapter 2, which identified Ano1 as a dimer, 
are a significant step toward understanding the physical properties of Ano1 and may be 
useful in the development of novel treatments.  Furthermore, our results show that 
HEK293 cells expressing Ano1 may be used for high throughput screening of new 
compounds. 
It is well documented that women are more susceptible to airway diseases and 
those suffering from genetic diseases, such as CF, deal with more severe symptoms 
[133-136].  However, the underlying cause of this discrepancy is not understood.  One of 
the main differences between male and female airways is the presence of different sex 
hormones.  Multiple studies have examined the effects of estrogen on airways 
physiology and health [136, 137, 146, 167].  In females with CF, elevated levels of 
estrogen are associated with an increase in acute exacerbations and can induce P. 
aeruginosa mucoid conversion [136].  Estrogen may also leave CF females prone to 
infection through SLPI-mediated inhibition of IL-8 [137].  In our studies presented in 
chapter 3, we discovered a novel regulatory mechanism utilized by estrogen to inhibit 
SOCE.  This ultimately inhibits CaCC and decreases ASL height [167].  We propose that 
CaCC is able to partially hydrate the ASL, but is inhibited when serum estrogen levels 
are increased, resulting in a complete loss of Cl- secretion.  As a result, clearance of 
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mucus may be further inhibited, leaving CF women prone to exacerbations and infection.  
Utilizing compounds that block the effects of estrogen, such as tamoxifen, may be useful 
in treating CF lung disease.  In fact, the Tarran lab has previously shown that tamoxifen 
can negate the effects of E2 on calcium signaling and ASL homeostasis [167]. 
These findings may also help explain why other chronic airway diseases, such as 
COPD and asthma, tend to be worse in females.  While there have been large 
epidemiological studies on sex differences in COPD and asthma [141, 142, 147, 241], 
very little has been done to identify an underlying mechanism(s).  Mucus hypersecretion 
is a characteristic of both COPD and asthma that is known to be regulated by Ca2+ and 
thus may be affected by non-genomic ESR1 mediated inhibition of STIM1 [142, 221].  
However, pathogenesis of these airway diseases is not fully understood and there are 
likely multiple factors, genetic and environmental, that affect disease progression.  
Nevertheless, our research may be a stepping stone to fully understand sex-linked 
differences in chronic airway diseases. 
 
4.6 Conclusion  
The studies in this dissertation are a significant contribution to our understanding 
of CaCC and sex-linked variations in CF.  Just five years ago the molecular identity of 
CaCC was unknown.  But with the discovery that Ano1 is an essential subunit of CaCC, 
there is now a significant amount of focus on this channel.  CaCC has been recognized 
as a therapeutic target for years, but with little success.  Now that Ano1 has arrived on 
the scene, there will most likely be a push to develop new and innovative compounds 
that can directly target Ano1.   
Our findings also promote the idea that CaCC is a physiologically significant ion 
channel in the airway.  Acute exposure to estrogen decreases ASL height by inhibiting 
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CaCC, which likely impacts disease progression in CF women.  Here, we have shown 
that estrogen inhibits STIM1 function by disrupting phosphorylation, which prevents 
induction of Ca2+ through Orai1.  As a result, cytoplasmic Ca2+ levels are not elevated 
sufficiently to activate CaCC.  A fuller understanding of this process may lead to new 
treatment strategies for females with CF and other chronic lung diseases. 
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Figure 4.1. EE-based birth control inhibits CaCC.  Mean changes in nasal PD in 
women during low E2 days or in women that are on EE-based birth control (n = 14).  
Nasal PDs were measured sequentially after administration of amiloride (ENaC 
inhibitor), isoproternal (CFTR activator), and UTP (CaCC activator) to the nasal 
epithelium.  ‘*’ indicates a significant difference.  Error bars represent mean ± S.E.M. 
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